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Abstract
Burkholderia pseudomallei (Bp) is a saprophytic, gram-negative aerobe and the causative agent of the
disease melioidosis. Melioidosis is an infectious disease that occurs in humans and animals and is
prevalent in Southeast Asia, northern Australia and other tropical areas. Transmission occurs through
direct contact with the organism via ingestion, inhalation, or through open wounds and skin abrasions.
Clinical presentation is extremely variable and can range from acute septicemia with bacterial
dissemination to distant sites, to an isolated pulmonary infection. Treatment of melioidosis can be
problematic because it is often difficult to diagnose and Bp is resistant to a diverse group of antibiotics.
Even with treatment, the mortality rate of melioidosis is 20 to 50%.
While this pathogen is not widespread in the United States, it is a significant U.S. health issue because of
its high potential for use as a biological weapon. The US Centers for Disease Control and Prevention
(CDC) and The Department of Health and Human Services (DHHS) has recognized Bp as a Tier 1 Select
Agent, meaning there is no effective vaccine against this high morbidity/mortality disease. Furthermore,
according the CDC, other factors including aerosol infectivity, the severity of infection, and the global
distribution of this pathogen makes it a potential bioterrorism agent that poses a threat to national
security, if intentionally released into populated areas.
There has been little investigation into the role of host genetic background as it relates to susceptibility
and/or resistance to Bp infection. It has been known for some time that inbred and recombinant inbred
mice exhibit differences in susceptibility to many intracellular pathogens and are thought to provide
excellent models for acute and chronic human melioidosis. Therefore, this project set out to identify host
genetic elements that contribute to differential immune responsiveness and/or susceptibility to a Bp
infection using a murine pneumonic challenge model. There is a high potential for discovery of host
genes/genetic networks that confer resistance or sensitivity to this dangerous and emerging pathogen
using inbred and BXD mouse strains as an in vivo modeling system of melioidosis.
We have utilized recombinant inbred BXD mice and a powerful array of complementary computer-based
modeling algorithms and databases collectively known as GeneNetwork. We infected parental mice and
32 BXD strains with 50-100 CFU of Bp (strain 1026b) and monitored survival and weight retention each
day over an eleven-day time course. Initial studies revealed that Bp infection elicits phenotypically distinct
innate immune responses in terms of survival and weight loss following pneumonic infection in parental
and BXD mice. Using the computational tools in GeneNetwork, we performed genome-wide linkage
analysis of our survival and weight loss phenotypic data to identify that survival is a complex trait
involving loci on chromosomes 5 and 7 and weight retention involves loci on chromosome 12. We then
analyzed and ranked several potential candidate genes within the significant and/or suggestive interval
on these chromosomes that appear to correlate with differential susceptibility to Bp infection. Several
genes have intriguing connections with innate immunity, regulation of Nf-kβ, apoptosis, cell cycle
regulation, nervous system development, calcium homeostasis, lipid transport, host cell growth and
development, and autophagy.
To date, there have been few published studies that have identified specific host genetic elements that
correlate with resistance and/or susceptibility to the acute form of melioidosis. Therefore, the
identification of key host genetic factors that control resistance or susceptibility to Bp is of much
importance. Results generated from this work will increase our understanding of the interactions between
Bp and its genetically diverse hosts, which will enhance the understanding of Bp pathogenesis and
increase the biological knowledge to help guide the progression and development of preventative and

therapeutic measures to a Bp infection as well as other high morbidity/mortality respiratory pathogens.
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ABSTRACT
Burkholderia pseudomallei (Bp) is a saprophytic, gram-negative aerobe and the
causative agent of the disease melioidosis. Melioidosis is an infectious disease that occurs
in humans and animals and is prevalent in Southeast Asia, northern Australia and other
tropical areas. Transmission occurs through direct contact with the organism via
ingestion, inhalation, or through open wounds and skin abrasions. Clinical presentation is
extremely variable and can range from acute septicemia with bacterial dissemination to
distant sites, to an isolated pulmonary infection. Treatment of melioidosis can be
problematic because it is often difficult to diagnose and Bp is resistant to a diverse group
of antibiotics. Even with treatment, the mortality rate of melioidosis is 20 to 50%.
While this pathogen is not widespread in the United States, it is a significant U.S.
health issue because of its high potential for use as a biological weapon. The US Centers
for Disease Control and Prevention (CDC) and The Department of Health and Human
Services (DHHS) has recognized Bp as a Tier 1 Select Agent, meaning there is no
effective vaccine against this high morbidity/mortality disease. Furthermore, according
the CDC, other factors including aerosol infectivity, the severity of infection, and the
global distribution of this pathogen makes it a potential bioterrorism agent that poses a
threat to national security, if intentionally released into populated areas.
There has been little investigation into the role of host genetic background as it
relates to susceptibility and/or resistance to Bp infection. It has been known for some
time that inbred and recombinant inbred mice exhibit differences in susceptibility to
many intracellular pathogens and are thought to provide excellent models for acute and
chronic human melioidosis. Therefore, this project set out to identify host genetic
elements that contribute to differential immune responsiveness and/or susceptibility to a
Bp infection using a murine pneumonic challenge model. There is a high potential for
discovery of host genes/genetic networks that confer resistance or sensitivity to this
dangerous and emerging pathogen using inbred and BXD mouse strains as an in vivo
modeling system of melioidosis.
We have utilized recombinant inbred BXD mice and a powerful array of
complementary computer-based modeling algorithms and databases collectively known
as GeneNetwork. We infected parental mice and 32 BXD strains with 50-100 CFU of Bp
(strain 1026b) and monitored survival and weight retention each day over an eleven-day
time course. Initial studies revealed that Bp infection elicits phenotypically distinct innate
immune responses in terms of survival and weight loss following pneumonic infection in
parental and BXD mice. Using the computational tools in GeneNetwork, we performed
genome-wide linkage analysis of our survival and weight loss phenotypic data to identify
that survival is a complex trait involving loci on chromosomes 5 and 7 and weight
retention involves loci on chromosome 12. We then analyzed and ranked several
potential candidate genes within the significant and/or suggestive interval on these
chromosomes that appear to correlate with differential susceptibility to Bp infection.
Several genes have intriguing connections with innate immunity, regulation of Nf-kβ,
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apoptosis, cell cycle regulation, nervous system development, calcium homeostasis, lipid
transport, host cell growth and development, and autophagy.
To date, there have been few published studies that have identified specific host
genetic elements that correlate with resistance and/or susceptibility to the acute form of
melioidosis. Therefore, the identification of key host genetic factors that control
resistance or susceptibility to Bp is of much importance. Results generated from this work
will increase our understanding of the interactions between Bp and its genetically diverse
hosts, which will enhance the understanding of Bp pathogenesis and increase the
biological knowledge to help guide the progression and development of preventative and
therapeutic measures to a Bp infection as well as other high morbidity/mortality
respiratory pathogens.
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CHAPTER 1.

INTRODUCTION

BURKHOLDERIA TAXONOMY AND GENOMICS
Burkholderia pseudomallei (Bp) belongs to the Burkholderia genus, which
contains over 40 species that inhabit a variety of ecological niches [1]. The majority of
species within this genus are non-pathogenic soil-dwelling bacteria, but a few species
(including Bp) are highly pathogenic to humans and animals, and can result in severe
disease [2]. This includes B. mallei, an obligate mammalian pathogen and the causative
agent of glanders. B. mallei primarily affects horses, donkeys and mules, and is extremely
virulent in humans [1]. A clinically important species of Burkholderia is B. cenocepacia,
which is a major cause of opportunistic infections in cystic fibrosis patients [1, 3]. This
genus also includes the Bp-like strain B. thailandensis, which coexists in the soil in
endemic areas, but as described in the literature, it is significantly less pathogenic than Bp
in hamsters and mice [3, 4].
Bp is an organism with a genome of great plasticity. It is also phenotypically
versatile, and this is reflective of a highly dynamic genome influenced by processes such
as recombination, mutations and gene acquisition through horizontal transfer [5, 6]. The
Bp genome (reference strain K96243) is one of the most complex bacterial genomes
sequenced to date, and possess two chromosomes of 4.07 and 3.17 megabase pairs [3, 7].
Bp shares a common set of 2590 genes (86% of genome) with other members of the
Burkholderia genus [3] that encode core functions such as cell growth and metabolism.
The other 14%, known as the accessory genome, is variably present across isolates and
encodes accessory functions such as adaptation and survival in different environments [3,
8]. The accessory genome also contains multiple genomic islands (GI) that have been
acquired through horizontal transfer, and act as a major source of genomic diversity [9].
These GI are likely associated with virulence, antibiotic resistance and the potential for
infection. However, more studies are needed to fully understand their association with
clinical outcomes [9, 10].
MELIOIDOSIS
Burkholderia pseudomallei and Melioidosis
Bp is a saprophytic, gram-negative aerobe and the causative agent of the disease
melioidosis [11]. Melioidosis is an infectious disease that occurs in humans and animals.
It is endemic in tropical areas between latitudes 20°N and 20°S of the equator, but is most
often reported in areas of Southeast Asia and Northern Australia [12]. In fact, this disease
has emerged as a major public health concern in Northern Australia and Southeast Asia
where it is the most common cause of fatal bacteremic pneumonias [13, 14] and carries a
mortality rate of 20% and 50%, respectively [7].
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Bp is an environmental pathogen and can be found in niches that predominate in
the tropics, such as rice paddies, stagnant waters and moist soils, [15, 16]. It is thought
that these habitats are the major reservoirs from which susceptible hosts acquire
infections [16]. Infection can result from percutaneous inoculation, inhalation, or
ingestion [3] and manifestations of disease are dependent on host pathogen interactions
and are extremely broad. Manifestations can range from rapidly lethal sepsis to chronic
low-grade infection, with the most common clinical picture being sepsis with bacterial
dissemination to distant sites [11, 17-19]. This picture is frequently associated with
pneumonia and formation of abscesses on the liver and spleen [20]. Infection can also
manifest in the skin, in bone, joints, soft tissue, or the prostate [19, 21-23], and can also
cause blood disease, kidney disease, heart disease, and more [20]. This broad spectrum of
clinical symptoms has earned Bp the nickname “The Great Mimicker”, since the clinical
symptoms of melioidosis imitate those of many other diseases. As a result, Bp infections
are frequently misdiagnosed [24] and this is often fatal [3]. Diagnosis is then reliant on
proper specimen collection and laboratory identification of the organism [23].
Additionally, melioidosis has been dubbed the “Vietnamese time bomb” [25] because of
lengthy disease latency observed in troops of all nationalities who served in areas with
endemic disease [25, 26]. This phenomenon has also been seen in returned travelers to
other countries [25, 27, 28].
Antibiotic Resistance and Treatment
Melioidosis has an extremely extended progression and cure is difficult without a
long course of antibiotic treatment [3]. To make matters worse, Bp is inherently
resistance to many antibiotics—including penicillin [29, 30], third-generation
cephalosporins [29, 31], aminoglycosides [29, 32, 33], rifamycins [28], tetracycline [3436], quinolones [30, 31, 34] and macrolides [29, 33, 35], which greatly hinders clinical
therapeutic options. According to a recent review by Wiersinga et. al. , “various
mechanisms of acquired antibiotic resistance have been identified in Bp and include
efflux pumps [33], enzymatic inactivation, bacterial-cell-membrane impermeability,
alterations in the antibiotic target site, and amino acid changes in penA (the gene
encoding the highly conserved class A β-lactamase)” [3, 37, 38].
Treatment of melioidosis lasts for 20 weeks and is divided into intravenous and
oral phases [3]. The initial intensive phase includes 10 to 14 days of intravenous
administration of ceftazidime, meropenem, or imipenem [3, 7, 8]. This is followed up
with an oral eradication therapy, usually with trimethoprim-sulfamethoxazole or
doxycycline for 3 to 6 months [3]. Despite this prolonged administration of antibiotics,
the rate of relapse is about 10%, which increases to almost 30% if antibiotic therapy is
discontinued at 8 weeks or less [39, 40]. The risk of relapse is also correlated to the initial
extent of disease [28]. As compared to children, who generally have a better prognosis,
adult patients fare worse and often require life-long follow-up [21, 41]. Unfortunately,
melioidosis has high mortality rates (up to 50%) despite the use of aggressive
antimicrobial therapy [1].
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Factors Associated with Disease Acquisition
Disease acquisition in endemic regions is associated with environmental and host
factors [7]. People with occupational or recreational exposure to contaminated soil or
water (rice farmers, military personnel, adventure travelers, eco-tourists, and construction
workers [42]) have a higher incidence of disease. This is most common during the rainy
season when aerosols are created, which results in repeated inhalation of Bp [43, 44].
Environmental sampling studies reveal there is a positive association between the
prevalence of disease and the degree of environmental contamination [7]. In addition to
environmental factors, data suggests that host factors play an important role in mounting
an immune response against infectious diseases [45] such as melioidosis. While healthy
persons can contract melioidosis, most patients in endemic regions have an underlying
predisposition [28], which suggests that the immunological status of the patient can
influence disease initiation and progression [15]. Specifically, diabetes mellitus (50% of
cases) and chronic renal disease (in 10 to 27% of cases) are the most common risk factors
for melioidosis [7, 15]. Other risk factors include heavy alcohol use, chronic pulmonary
disease, and cancer [3, 21]. Furthermore, since melioidosis is associated with a broad
range of clinical presentations, there is a possibility that the route of infection is one of
the many factors that may influence disease outcome [46].
It has been established through published genome wide studies that susceptibility
to major infectious diseases in humans may be associated with common polymorphisms
[47, 48]. These findings include a correlation between human leukocyte antigen (HLA)
polymorphisms and the type and/or intensity of the immune response that develops in
response to a Bp infection [49]. Additionally, a study by Nuntayunuwat et.al found that
polymorphisms in cytokine-related genes maybe be a factor in susceptibility to infection
with Bp [50]. Such data highlight the importance of investigating the role of host genetic
variation with regards to susceptibility to disease [48]. This also leads to the notion that
there may be an immunogenetic basis in clearing a Bp infection. However, the impact of
specific genes or genetic backgrounds in humans that contribute to the susceptibility or
resistance to many major diseases [51], including melioidosis, has yet to be determined.
Animal Models
A variety of animals have been used in experimental models of melioidosis,
including chicken [52], rats [53], guinea pigs [54] and inbred mouse strains [55, 56]. The
murine infection model has also been used to show both the importance of the host
genetic background as well as host responses on the progression of a Bp infection [28].
BALB/c mice [57, 58] and DBA/2J (D2) [55, 59] mice are known to be extremely
susceptible to the acute form of melioidosis, while C57BL/6 (B6) [28, 55, 56, 58] mice
exhibit a heightened level of resistance to the acute form of melioidosis, and tend to
develop a chronic form of the disease. The acute melioidosis observed in BALB/c and D2
mice is characterized by significantly higher levels of pro-inflammatory cytokines,
including a hyper-production of IFN-γ. This results in a cellular response that fails to
control the infection and contributes to tissue damage and multiple organ failure [56]. In
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contrast, B6 mice develop a chronic infection that is associated with a moderate but
transient induction of pro-inflammatory cytokines, allowing the temporary sequestration
of Bp within phagocytes and induction of an adaptive immune response [56, 60]. The
heighted level of resistance exhibited in B6 mice is thought to have a genetic basis.
Undeniably, these mouse studies illustrate the potential importance of host genetic effects
to Bp infection by highlighting major differences between distinctive inbred strains [48,
56, 61].
POTENTIAL FOR BIOTERRORISM
As a result of Bp’s biodefense implications, broad-host-range infectivity and its
low infectious dose, the CDC and DHHS have recognized Bp as a Tier 1/ Category B
Select Agent [37, 62, 63]. According to the CDC, agents within this category are those
that are moderately easy to disseminate, have an amenability to aerosolize, result in a
severe course of infection and no have effective vaccine. Other factors include the
intrinsic antibiotic resistance and global distribution of this pathogen, which makes it a
potential bioterrorism agent that poses a threat to national security if intentionally
released into populated areas [64, 65]. While Bp is not widespread in the U.S., it is a
significant U.S. health issue because of its high potential for use as a biological weapon.
In recent years, knowledge on melioidosis has increased tremendously, due to more
research groups working with Bp as a result of it being recognized as a biological threat
agent [66]. Furthermore, the select agent listing of this pathogen subjects all research
using Bp to strict federal guidelines that govern its acquisition, possession and use. Only
trained personnel within a Biosafety Level 3 (BSL-3) facility (or national equivalent)
should handle the organism [19, 23]. This hinders research on Bp by those research
institutions that lack these containment laboratories.
SYSTEM GENETICS APPROACH TO MELIOIDOSIS
As described above, melioidosis is associated with a variable clinical presentation.
The varying responses have been attributed to heritable variation, which predisposes an
individual to certain disease outcomes [67, 68]. Rather than independently investigate
each biochemical, cellular and genetic factor in understanding melioidosis, it is far more
efficient to instead utilize recent computational and technological advances to
quantitatively examine large numbers of DNA sequence variations, transcript levels, and
proteins [69, 70]. By integrating this comprehensive data, it is possible to identify the
commonalties that link the associations between disease and DNA, as well as develop
molecular networks by which these links can be traced [70]. As such, it is useful to
employ a system genetics approach to identify and characterize genetic loci that
contribute to resistance and/or susceptibility to melioidosis.
System genetics is an emerging branch of systems biology that seeks to identify
relationships between genetic variants and systems of biological components (i.e.
molecules, cells) in complex traits and disease [71]. Most often, mapping populations are
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used to understand the relationship between phenotype and genotype relative to complex
traits. The phenotypic and genotypic data that is generated is compiled into complex
networks, which are then used to discriminate genetic variation among the mapping
population [55, 72, 73]. This approach provides an informative view into the general
framework of complex traits and the flow of biological information [69]. Furthermore, in
an attempt to better understand both biology and disease, systems genetics has become a
progressively important approach in bridging this gap [69]. The idea is that variations in
DNA (i.e. single nucleotide polymorphisms), which associate with a particular disease or
response (melioidosis in this case), impact the complex physiological processes involved
with the response through molecular and cellular events, tissue, and organismal
phenotypes [70]. Statistical methods and computational algorithms can be used to
identify associations between multi-level phenotypes and the underlying genetic variants
as previously described [74].
GENETIC REFERENCE POPULATIONS AND QTL MAPPING
General Information
Genetic reference populations (GRP) are often used in system genetics studies.
They are well characterized genetically, and thus are ideal to examine phenotypic traits
[69]. Usually, these populations are sets of inbred strains that have been designed to
incorporate levels of genetic complexity that mimic aspects of human populations [75].
Furthermore, they are genetically stable and therefore reproducible, thereby enabling
extensive replication studies [75, 76]. As a result, phenotypic data can be obtained over
time from various experiments and investigators, and then integrated together [77].
Moreover, one of the initial motivations of using GRP is that researchers do not have to
undergo the difficult and costly task of genotyping individuals for each experiment.
Recombinant inbred (RI) mouse strain lines (RILs) are a type of GRP that
provide genetic variation for molecular genetic studies and can serve as powerful tools
for genetic mapping. Donald Bailey and Ben Taylor first developed and characterized a
collection at the Jackson Laboratory in the 1970s [78]. RILs can serve as powerful tools
for genetic mapping and are commonly used in linkage studies [79] to map the locations
of DNA sequence differences (i.e. quantitative trait loci-discussed later) that contribute to
alterations in phenotype in these model organisms. These RILs allow tight experimental
control [75] where variance associated with environmental factors and technical errors
can be suppressed to low levels; and each recombinant genome is represented by an
entire isogenic line [76]. Conventional RILs are created by crossing two inbred parental
strains. This crossing initiates the formation of the heterozygous F1 progeny [80], which
will be identical to its siblings. The F1 progeny are crossed to produce the F2
generations, which is followed by repeated selfing or sibling mating for 20 or more
generations. This breeding scheme makes certain these strains are at least 99% inbred
[81, 82]. This also ensures fixation of the recombined chromosomes in that, animals from
each individual RI strain are genetically identical and homozygous at every locus in their
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genome [80, 83-85]. In other words, this process creates new RILs that: (1) possess two
matching copies of every chromosome, (2) are genetically different from one another and
(3) have a genome that is a pure mixture of the parental strains [79]. Additionally, RI
strains acquire large amounts of recombination as they are created, which is particularly
useful for mapping complex traits [79, 84, 86]. Furthermore, phenotypic data from these
RILs can be collected by many different research groups, at different ages, and under
various environmental conditions [87] and stored in databases for comparison [77, 88].
The BXD Mouse Family
BXDs (C57BL/6J X DBA/2J) are the largest RI strain panel currently available
and represent a commonly used GRP. These strains were derived by crossing B6 and D2
and inbreeding progeny for 20 or more generations [89] resulting in a unique
combination of parental alleles between the different progeny strains (Figure 1-1). The
BXD RI mapping panel was first generated by Ben Taylor at the Jackson Laboratory
[77], producing the first 30 lines and subsequently lines 33-42 [90]. Lines 43-100+, also
called the Advanced Intercrossed Lines (AILs), were produced by Williams, Lu and
colleagues at The University of Tennessee Health Science Center [84]. Breeding of the
AILs is initiated in the same manner as the RI strain sets however, mice of the F2
generation and each subsequent generation are intercrossed for 9-14 generations before
initiating inbreeding. As a result, the highly recombinant AIL population incorporates
approximately 1.7 times more recombination events [91] as standard RI strains, and a 48X higher level of recombination relative to the F2 intercross progeny. This level of
recombination significantly adds to the power of the BXD RI lines as a whole in
achieving a higher mapping precision [79, 92].
The BXD strain set is fully genotyped and each line is genetically distinct with a
defined and fixed genetic architecture [73]. There are currently over 100 BXD strains for
which genotype data is publically available. They have the potential to display a broad
range of susceptibilities to a Bp infection [89] and also provide high precision mapping
[93]. The idea of the use of BXD mouse strains is advantageous because BXD mice
incorporate a well-defined level of genetic and phenotypic variation. Furthermore, since
each strain has a fixed genome, it is possible to resample a given phenotype multiple
times. The BXD panel consists of almost 3,800 informative markers including, single
nucleotide polymorphisms (SNPs), polymorphic insertions and deletions (indels) and
microsatellites disturbed throughout the genome [91, 94]. This makes the discovery of
genetic loci that contribute to quantitative traits relatively fast and straightforward. As
stated earlier, data generated using the BXD family of strains is both “cumulative and
comparable”[87], where phenotypes can be quantified using the same set of genotypes,
representing yet another advantage of this RIL [95].
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Figure 1-1. Breeding scheme used to generate the panel of BXD recombinant
inbred strains.
BXD recombinant inbred mouse strains that were generated by the inbreeding of B6 x D2
F1 offspring.
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QTL Mapping
Allelic variation exists among natural populations and inbred strains, and this is
reflective of the segregation of quantitative trait loci (QTLs) [96]. QTLs are stretches of
DNA that are closely linked to genes that underlie a phenotype of interest. QTL analysis
has been proven to be an invaluable tool to help unravel heritable traits, by enabling
researchers to map different quantitative traits back to the genomic location involved in
the regulation of these phenotypes.
QTLs are identified by their linkage to polymorphic marker loci (SNPs, indels,
microsatellites) [94] that are distributed throughout the genome of the reference
population. A large number of these polymorphic loci are required to obtain adequate
power for informative QTL mapping. QTLs can be identified through their genetic
linkage to visible marker loci with genotypes that can be readily classified [94, 97]. As
such, markers that are genetically linked quantitative trait will segregate more often with
trait values, whereas unlinked markers will lack an association with the phenotype [94,
98]. The principal goal of a QTL analysis is to identify all QTLs linked to a trait and
discern whether phenotypic differences are mainly due to a few loci with large effects, or
many loci with small effects [98]. However, QTL mapping usually results in identifying
genes that have major effects on the trait [99] but in this instance, sample size is a critical
factor [98]. Furthermore, an additional advantage to identifying QTLs are the insights
gained into the development and physiology of complex traits on a molecular level [96].
QTL mapping has been used to successfully identify genomic regions underlying a
variety of human diseases such as chlamydial infections [100], Influenza [73] and
alcoholism [101].
QTL mapping requires a few essential steps: initially, the trait must be measured
in the parental (or progenitor) inbred strains that were used to create the GRP that will be
used for the study before culminating studies in the RILs (i.e. BXD mice). Since the
individuals in GRP have polymorphic genes (i.e. genes that exist in multiple forms), there
is a high potential for distinctive strains to exhibit differences in phenotype. Once a
differential phenotype is established in the parents and the RILs, the next step is to
determine the heritability of the variation in the trait being measured. Heritability
describes the genetic influence of the observed variation in the trait, as opposed to
variation caused by environmental factors or technical errors. The third step is to prepare
the phenotype and genotype data from the individuals for QTL mapping. Once this step is
completed, interval mapping can be carried out which will identify any regions of the
genome that may contribute to the phenotypic trait that is being measured.
Simultaneously, statistical tests (i.e. permutation tests and bootstrapping) are performed
to establish confidence intervals. Once a QTL has been identified, subsequent testing can
be used to further resolve the precise location and mechanism of the gene effect [102].
For this study, we used GeneNetwork (GN) to perform our QTL mapping
analyses. GN is an extensive online tool that contains a powerful array of complementary
computer-based modeling algorithms and databases and uses interval mapping to
approximate the location of QTLs throughout the genome [103, 104]. These
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bioinformatics tools allow for the reconstruction of genetic networks that confer
resistance and/or susceptibility to many infectious diseases [105]. GN combines a large
number of transcriptome and sequence data sets that are acquired from many species
including humans, mice and some plants [106]. This allows for rapid integration and
analysis of experimentally obtained phenotypes with genetic and gene expression data
through QTL mapping. Specifically, once trait data is uploaded into GN, interval
mapping can be completed to establish if there is a significant or suggestive linkage
between the phenotypic trait of interest and the genotype. Permutation tests are used to
calculate the significant (p=0.05) and suggestive values and are depicted as a likelihood
ratio statistic (LRS). The LRS signifies that a particular region of a chromosome contains
a gene(s) that is influencing the variation in the phenotypic trait. The higher the LRS, the
more likely it is that a gene in that portion of the chromosome is associated with the trait
being measured.
ORGANIZATION OF THE DISSERTATION
The work presented in this dissertation demonstrates the use of a murine model of
Bp infection and a forward genetics approach to gain a better understanding of the
interactions between Bp and its hosts. We have identified several host loci that may
contribute to resistance and/or susceptibility to a Bp infection.
In chapter 3, we exploit a powerful mouse genetics resource that consists of a
large family of BXD type recombinant inbred strains, to perform genome-wide linkage
analysis of the weight loss phenotype following pneumonic infection with Bp. We
initiated this project by infecting parental mice and 32 BXD strains with 50-100 CFU of
Bp (strain 1026b) and monitored weight retention each day over an eleven-day time
course. Using the computational tools in GeneNetwork, we performed linkage analysis to
identify intervals on chromosomes 4, 2, 17, and 12 that appear to control the weight
retention trait. We then analyzed and ranked positional candidate genes in these intervals,
several of which have intriguing connections with innate immunity, calcium homeostasis,
lipid transport, host cell growth and development, and autophagy.
Based on the insights we gained in chapter 3, we extended our investigation
beyond weight retention to examine survival and time-to-death following pneumonic Bp
infection. The results in chapter 4 show that D2 mice are significantly more susceptible to
pneumonic Bp infection than B6 mice. We then utilized the BXD RI strain panel to
perform genome-wide linkage analysis using survival and time-to-death (following
pneumonic infection with 50-100 CFU of Bp 1026b) as phenotypic readouts. The BXD
mice displayed a wide range of susceptibilities to pneumonic Bp infection and these
studies revealed that survival is a complex trait that is dependent on host loci located on
chromosomes 5 and 7.
This dissertation also explores the challenges of working with infectious agents
(such as Bp) in BSL-3 level containment laboratories. In chapter 5, we characterize the
effectiveness of paraformaldehyde fixation for inactivation of cell samples infected with
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Bp and Francisella tularensis (Ft). Both of these intracellular pathogens are Tier 1 select
agents and require BSL-3 containment. In this study, we tested varying concentrations
(0.5%, 1.0%, 2.1%, 4.2%) of paraformaldehyde to validate the inactivation kinetics
required to completely inactivate these bacteria to allow for removal of samples from a
BSL-3 laboratory for flow cytometric analysis using BSL-2 containment practices. We
found that these cells are completely inactivated via a 5-minute treatment with 4%
paraformaldehyde and that Bp is significantly more sensitive to paraformaldehyde
treatment than Ft [107].
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CHAPTER 2.

MATERIALS AND METHODS

BACTERIAL STRAINS AND GROWTH CONDITIONS
Burkholderia pseudomallei strain 1026b (Bp) was obtained from BEI Resources
Biodefense & Emerging Infections Research Resources Repository (Manassa, VA). Bp
was cultured in LB broth (tryptone [10g/liter], yeast extract [5g/liter], and NaCl
[10g/liter]). Challenge stocks were prepared by performing an overnight culture that was
then sub-cultured the following day until mid-log growth phase was achieved (ABS=1.0
at 600nm). Bacteria were then pelleted by centrifugation, resuspended in fresh LB
medium containing 20% glycerol, and frozen in aliquots. These challenge stock aliquots
were stored at -80˚C until needed. All work with Bp was performed under biosafety
level-3 (BSL-3) containment according to policies and standard operating procedures
approved via the University of Tennessee Health Science Center (UTHSC) Committee
On Biocontainment and Restricted Entities (COBRE), a subcommittee of the UTHSC
Institutional Biosafety Committee (IBC). The UTHSC has been approved for select agent
work by the CDC.
MICE
C57BL/6J, DBA/2J, and all BXD strains of mice used in these studies were
obtained from our in-house breeding colony in the Regional Biocontainment Laboratory
(RBL) at UTHSC and were used between the ages of 8-16 weeks. Mice were housed in
an AALAC accredited and CDC-select agent program approved facility within an
Allentown Biocontainment Unit BCU2000 caging system with gamma-irradiated food
and autoclaved water available ad libitum. All experimental protocols involving animals
were reviewed and approved by the UTHSC IACUC.
INTRANASAL INSTILLATION OF MICE WITH BP
Prior to each challenge procedure, an aliquot of frozen challenge stock was
thawed and diluted as needed with PBS to reach the required dose of Bp (50-100
CFU/dose). Prior to instillation, mice were anesthetized using isoflurane delivered using
a SurgiVet® Vaporstick small animal anesthesia machine equipped with a Classic T3™
isoflurane vaporizer (Smith Medical, Dublin, OH). Mice were exposed to 2.5% isoflurane
delivered in O2 (2 L/min) within a 1-liter induction chamber until a state of areflexia was
reached. Intranasal administration of each challenge dose (50μl total volume) was
administered immediately after the mouse was removed from the induction chamber by
pipetting the inoculum onto the outer edge of the nares. No supplemental anesthesia or
oxygen was administered following removal of mice from the induction chamber. Mice
were held in a tilted supine position with their heads elevated to between 60 and 75
degrees above their feet during and after instillation (for approximately 1 minute).
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BP BURDEN ENUMERATION
Determination of Bp burdens in the lungs and livers collected from infected mice
was performed via dilution plating as previously described [108-110]. Briefly, lungs of
Bp-infected mice were removed aseptically and homogenized (using a closed tissue
grinder system, Fisher Scientific, Pittsburgh, PA) in one ml of sterile PBS, and the final
volume was adjusted to 1.25 ml with PBS. To disrupt cells (releasing Bp), 0.25 ml
disruption buffer (2.5% saponin, 15% BSA, in PBS) was added with light vortexing.
Appropriate dilutions of each sample were then plated in duplicate using an Eddy Jet
spiral plater (Neutec Group Inc., Farmingdale, NY) on LB agar plates and incubated at
37qC for 48-72 hours. Colonies were counted using a Flash & Go automated colony
counter (Neutec Group Inc.).
MONITORING OF MICE POST CHALLENGE
Mice were observed daily for signs of morbidity for a period of 10-11 days post
infection. Each mouse was weighed daily as an additional measure of disease
progression. Moribund mice were euthanized to prevent unnecessary pain and/or
discomfort. Scoring for linkage analyses was as follows: mice that succumbed to acute
melioidosis where given a score of “0” while those that survived were given a score of
“1”.
RNA ISOLATION AND FUNCTIONAL GENOMICS
RNA expression was analyzed in lungs, 24 hours post-infection from resistant
(BXD50, BXD70) and susceptible (BXD63, BXD09, BXD27) BXD mice infected with
50-100 CFU of Bp 1026b. A minimum of three RNA samples per strain was obtained.
For RNA isolation, lungs were immediately suspended in 1mL of RNAlater (Qiagen,
Valencia CA) and placed in 4°C. Following homogenization (using a closed tissue
grinder system, Fisher Scientific, Pittsburgh, PA) total RNA was prepared from the lungs
and submitted to a cleanup protocol using the RNeasy Midi Kit (Qiagen, Valencia CA)
following the manufacturer’s protocol. Contaminating DNA was removed using a
RNAase-Free DNAase Set according to the manufacturer’s protocol (Qiagen, Valencia
CA).
RNA quality was confirmed by UV spectrophotometry and RNA quantity was
confirmed by analysis on an Agilent 2100 bioanalyzer (Agilent Technologies, Santa
Clara, CA). Total RNA was processed in the Molecular Resource Center at UTHSC.
RNA-seq reads were trimmed to remove low quality 3’ ends using Trimmomatic (version
0.32) with the following parameters: TRAILING:15 SLIDINGWINDOW:5:15
MINLEN:35. Reads were aligned to the C57BL/6J reference mouse genome (mm10)
using TopHat2 (a splice aware aligner, version 2.0.12) with the following parameters: -library-type fr-firststrand --max-intron-length 300000 --b2-sensitive. HTSeq-count
(version 0.6.1) was used with the following parameters: --stranded=reverse -r 'pos' to
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count the number of reads that overlap each transcript in the mouse Ensemble gene model
(GRCm38, version 76). The resulting count files were used as input to DESeq2 (version
1.3.69). DESeq2 uses a negative binomial distribution for statistical inference about
differential expression of genes. We selected genes that showed differential expression
between x and y at FDR of 0.05.
GENOME-WIDE LINKAGE ANALYSIS
QTL/interval mapping of BXD weight retention and survival phenotypic data was
performed using GeneNetwork (www.genenetwork.org). Interval mapping tests for the
presence of QTLs across the entire genome and summarizes the strength of linkage as a
likelihood ratio statistic (LRS) [84, 103]. We used a permutation test to establish
empirical significance criteria at a genome-wide p value of .05 [100]. The original data
sets can be obtained at www.genenetwork.org with the following identification numbers:
survival: 16330, time of death: 16331, percentage weight loss Day 1: 16332, Day 2:
16333, Day 3: 16334, Day 4: 16335, and Principle component 1: 16350.
HERITABILITY CALCULATION
To assess heritability, we computed a single factor ANOVA with the mouse
strain as the independent measure and percentage weight loss as the dependent measure.
In short, the variance between strains and variance within strains were calculated. The Fstatistic was calculated as the ratio of the variance between strains to the variance within
strains. The total variance was calculated as the sum of variance between strains and
variance within strains. Heritability was calculated as ratio of variance between strains to
the total variance.
STATISTICAL METHODOLOGY
Statistical analyses for some figures in chapter 3 were performed using GraphPad
Prism software (GraphPad Software, La Jolla, CA) as indicated in the figure legend. All
other statistical analyses were performed using the algorithms built into GeneNetwork or
as described in the text.
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CHAPTER 3. GENETIC CONTROL OF WEIGHT LOSS DURING
PNEUMONIC BURKHOLDERIA PSEUDOMALLEI INFECTION
INTRODUCTION
Burkholderia pseudomallei (Bp) is a saprophytic, gram-negative aerobe and the
causative agent of the disease melioidosis [7]. Melioidosis is an infectious disease that
occurs in humans and animals and is prevalent in S.E. Asia, N. Australia and other
tropical areas [111]. Transmission occurs through direct contact with the organism via
ingestion, inhalation, or through open wounds and skin abrasions [7]. Clinical
presentation is extremely variable and can range from acute septicemia with bacterial
dissemination to distant sites, to an isolated pulmonary infection [7, 8]. Treatment of
melioidosis can be problematic because it is often difficult to diagnose and Bp is resistant
to a diverse group of antibiotics [34]. Even with treatment, the mortality rate of
melioidosis is 20 to 50% [21, 112]. Although this pathogen is not endemic in the United
States, it is a significant U.S. health issue because of its high potential for use as a
biological weapon [56, 113]. In fact, Bp has been classified as a Tier 1 Select Agent by
APHIS and DHHS and as a Biodefense category B pathogen by NIAID. Furthermore,
other factors including aerosol infectivity, the severity of infection, and the global
distribution of this pathogen makes it a potential bioterrorism agent that poses a threat to
national security, if intentionally released into populated areas [114].
The basis of the variable progression of melioidosis in Bp-infected individuals has
not been determined, to date. There is evidence that differential susceptibility to Bp has
an immunogenetic basis. For instance, one study revealed that polymorphisms in
cytokine-related genes may be a factor in susceptibility to infection with Bp [68].
Another report revealed a correlation between human leukocyte antigen (HLA)
polymorphisms and the type and/or intensity of the immune response that develops in
response to a Bp infection [49]. These findings are not surprising in light of findings that
genetic factors play a key role in susceptibility to a wide range of other infectious
diseases. Published findings have identified host genetic factors that are critical for
variable susceptibility to intracellular parasites [115], viruses [116-120], and both
intracellular [74, 100, 121] and extracellular [122] bacterial pathogens. Moreover, recent
genome-wide studies have established novel associations between common
polymorphisms and susceptibility to several infectious diseases that are responsible for
significant morbidity and/or mortality in humans [73, 100, 123, 124].
The murine model of B. pseudomallei infection is considered to be an excellent
model for both the chronic and acute forms of human melioidosis [56, 60, 125]. Studies
*Reprinted with permission. Emery, F.D., et al., Genetic control of weight loss during
pneumonic Burkholderia pseudomallei infection. Pathogens and disease, 2014. 71(2): p.
249-64.
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in inbred strains of mice have established the importance of the host genetic background
on the progression of Bp infection. C57BL/6J (B6) mice are known to be relatively
resistant to the acute form of melioidosis and tend to develop disease that progresses
significantly slower than that observed in the much more susceptible BALB/c [56, 60] or
DBA/2J (D2) [61] inbred strains. To date, there have been few published studies that
have identified host-genetic elements that correlate with the progression of melioidosis.
In this report, we have used a panel of recombinant inbred (RI) mouse strains, that were
generated by inbreeding of B6 x D2 F1 offspring (BXD), to perform genome-wide
linkage analysis for the identification of host genetic loci that correlate with the
differential weight loss of B6 and D2 parental strains during acute pneumonic
melioidosis.
RESULTS
Our initial studies with a pneumonic challenge model (intranasal instillation)
using 50–200 CFU of Bp 1026b confirmed the previously published observation [61] that
B6 are more resistant than D2 to Bp infection (Figure 3-1). Subsequent studies in a
cohort of BXD strains (using a challenge dose of 50–100 CFU) revealed a range of
susceptibility to melioidosis. Interestingly, female D2 mice (as well as females of several
BXD strains) were significantly more resistant to pneumonic Bp infection than their male
counterparts (Figure 3-2). This result indicates that there are sex-based host factor(s) that
influence the susceptibility/resistance phenotypes of at least some mouse strains to Bp
infection. Based on these findings, we performed all of the following studies exclusively
in male mice.
We performed a series of experiments in which a cohort of 32 BXD strains as
well as the B6 and D2 parental strains were challenged via intranasal instillation with 50–
100 CFU of Bp 1026b and then monitored for disease progression by measuring weight
loss over the next 11 days (see Table A-1 in Appendix for BXD strain group sizes).
Based on survival, the BXD strains could be logically broken into three categories based
on their susceptibility to pneumonic Bp infection: 1) susceptible, 2) intermediate
susceptibility, and 3) resistant. An evaluation of weight loss in these three groups of BXD
genotypes predictably revealed that the resistant strains generally lost less weight than the
intermediate susceptibility strains, and especially the susceptible BXD strains following
infection (Figure 3-3). However, there were several BXD genotypes that did not follow
this pattern. For instance BXD9 was highly susceptible to Bp infection and all succumbed
to infection by day 4 post-infection. Interestingly, these mice lost less of their body
weight than most of the strains in the study, including the BXD genotypes that were
resistant to Bp. Likewise, BXD81 lost weight slower than the other susceptible strains
despite the fact that they all succumbed to melioidosis by day 4 post-infection. In
contrast, BXD38 survived the challenge while losing weight faster than any other strain
in the study. Moreover, BXD strains within each of these phenotypically distinct
subgroups—susceptible, intermediate susceptibility, and resistant—displayed a wide
range of weight change kinetics (Figure 3-4). These findings indicated that weight
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Figure 3-1. DBA/2J mice are significantly more susceptible than C57BL/6J mice
to Burkholderia pseudomallei.
Panel A: C57BL/6J and DBA/2J mice (15/strain) were challenged with 50 CFU Bp
1026b via intranasal instillation. Mice were sacrificed (5/strain) each day and lungs were
collected via sterile dissection. The bacterial burdens in the lungs of each mouse were
determined via dilution plating and are reported as CFU/mg of lung tissue. Statistical
analysis was performed using a two-way ANOVA with Bonferroni posttests. Panel B:
C57BL/6J and DBA/2J mice (13/strain) were challenged with 50-100 CFU Bp 1026b via
intranasal instillation and were monitored for survival over the next 11 days. Statistical
analyses were performed using Log-Rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon
tests.
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Figure 3-2. Differential susceptibility of male versus female DBA/2J and BXD
mice to pneumonic B. pseudomallei infection.
The indicated strains of mice were challenged with 50-100 CFU of Bp via intranasal
instillation and were monitored for survival over an 11-day period. Survival data is
displayed in a Kaplan-Meier plot and statistical analyses were performed using Log-Rank
(Mantel-Cox) tests.
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Figure 3-3.

Weight loss of BXD genotypes following pneumonic Bp infection.

The cohort of BXD mice were weighed daily following intranasal instillation with 50-100
CFU of Bp 1026b as a measure of morbidity. For comparative purposes, the data are
presented in three panels depending on the susceptibility of each strain to Bp infection.
The genotypes that all experienced 100% mortality are shown in the panel labeled
“Susceptible”. Those that experienced 100% survival are shown in the panel labeled
“Resistant”. The genotypes that had at least one survivor or at least one mortality are
shown in the panel labelled “Intermediate Susceptibility”. The data are plotted as the
mean weight loss (± SEM).
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Figure 3-4. Bar graph (by rank) of percentage weight loss on days 1 through 4
post-Bp infection.
The BXD and parental mouse cohort were weighed daily after intranasal challenge with
50-100 CFU of Bp 1026b as a measure of morbidity and the percentage of weight loss
(mean ± SEM) is shown for each mouse genotype on the indicated day post-infection.
The “susceptible” strains (100% mortality) are indicated with a grey bar, “resistant”
strains (100% survival) are indicated with a white bar, and “intermediate” strains (at least
one mouse died) are indicated with crosshatched bars. The parental B6 and D2 mice are
indicated with black and brown bars, respectively. Red asterisks indicate that at least one
mouse from that genotype succumbed to infection.
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change kinetics generally tracks with disease progression, but is not a completely reliable
indicator of susceptibility to pneumonic Bp infection.
Heritability and Variance of Weight Loss Traits
We estimated heritability as the main effect on body weight relative to the starting
weight by ANOVA. Heritability increased from day 1 through to day 3–4 from ~70 to
93% (Figure 3-5a). Correlations among the four sequential and non-independent weight
loss estimates are high, and the first principal component accounts of ~75% of the total
variance (Figure 3-5B and Figure 3-5C), and GeneNetwork Trait 16350 for the
eigentrait associated with the principal component.
Identification of Host Loci that Are Covariant with Weight Loss during Pneumonic
Bp Infection
We performed genome-wide linkage analysis using weight loss relative to
baseline. Mapping results are volatile for days 1 and 2 (Figure 3-6), with suggestive loci
on Chr 4 (LRS of ~15 from 7 to 11 Mb with B alleles contributing to increased weight
loss; Figure 3-7A), on distal Chr 2 (LRS of ~12 from 178 to 182 Mb, high B allele;
Figure 3-7B), and on proximal Chr 17 (LRS of ~14 from 6 to 13 Mb, high D allele;
Figure 3-7C). Two of these suggestive loci have an effect that does not conform to
expectation based on parental strain weight loss (D2 high, B6 low). In contrast, we detect
a single significant and consistent QTL on Chr 12 for weight loss on days 3 and 4 (and
remaining stable over the remaining timecourse: see Figure A-1) that does conform to
expectation based on the parental strain difference (Traits 16334 and 16335). This Chr 12
locus peaks between 80 and 87 Mb near the Ttc9 gene. The LRS peak of 16–18 is near
the genome-wide significance threshold. Although it does not affect the position of this
peak, the LRS is boosted to 21 by including parental phenotypes (Figure 3-7D). As
shown in Figure 3-5, a principal component analysis for weight loss at all days, also
supports a single locus on Chr 12 with increased sensitivity being associated with the D
allele (Trait 16350).
Identification of Candidate Host Genes that May Contribute to Weight Loss
Kinetics Following Pneumonic Bp Infection
We analyzed each of the loci to identify and evaluate potential candidate genes.
We considered and weighted several factors including: (1) mRNA expression levels at or
above background in the lungs and spleen, (2) genes that are associated with local genetic
control (so called cis eQTLs) in the lung; and (3) genes with one or more
nonsynonymous SNPs or indels between the parental B6 and D2 genotypes. These
factors were combined into a ranking score scale (0 to 4) using the QTLminer software
[126]. The highest scoring candidates are indicated in Figure 3-7 (right hand panels).
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Figure 3-5. Principal component analysis, heritability, and correlations among
weight loss traits during the early stages of pneumonic melioidosis.
Panel A: Heritability of weight loss increases from day 1 to day 4. Panel B: A
correlation matrix of Pearson (lower left) and Spearman rank (upper right) correlations,
along with the first principal component (PC). The numbers listed in orange or red text
indicate correlation indices of 0.5-0.7 and 0.7 to 1.0, respectively. Panel C: Pearson’s
Scree plot shows that the first PC accounts for approximately 75% of the strain variance
in weight loss.
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Figure 3-6. Genome-wide linkage analysis for percentage weight loss over the 4
days following pneumonic challenge with Burkholderia pseudomallei.
Genome-wide interval maps of percentage weight loss of all BXD genotypes and parental
strains at each time point are shown as indicated. The blue line indicates LRS scores
across the entire genome. Thin red and green lines indicate that B6 or D2 alleles increase
trait values, respectively. The mouse chromosomes are identified in the upper x-axis, the
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively.
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Figure 3-7. Detailed maps of the QTLs contributing to weight loss during the
early stages of pneumonic Bp infection.
The critical intervals on Chrs 4 (Panel A), 2 (Panel B), 17 (Panel C) and 12 (Panel D)
were identified based on bootstrap analysis (frequencies of peak LRS indicated with
yellow bars) and peak shapes. The critical intervals for candidate gene analysis for each
chromosome were: Chr 4: 7-14 Mb, Chr 2: 179.25-180 Mb, Chr. 17: 9.5-11.5 Mb, Chr.
12: 80-86 Mb. The density of SNPs present in the BXD strains is indicated by orange
chatter along the x-axis. The multicolored chatter along the top of the graph represent the
open reading frames within the interval. The blue line indicates LRS scores across the
entire genome. Thin red and green lines indicate that B6 or D2 alleles increase trait
values, respectively. The mouse chromosomes are identified in the upper x-axis, the
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively. Right
hand panels: The highest ranking candidate genes within each interval (according to
QTLminer scores) are indicated along with their LRS score and their relative expression
levels in normative tissues.
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More comprehensive lists of candidates for each of the QTLs are shown by day and trait
identifiers in Tables 3-1, 3-2, and 3-3.
DISCUSSION
Both humans and distinct inbred mouse strains display a range of disease
progression following Burkholderia pseudomallei infection. In this study, we employed a
panel of recombinant inbred BXD genotypes to identify regions of the murine genome
that are responsible for their variable weight loss during the course of Bp infection. We
performed genome-wide linkage analysis using percentage weight loss over a four-day
time course following pneumonic infection with Bp 1026b to identify host genes
responsible for differential progression of melioidosis. We found that the weight loss trait
is controlled in a time-dependent manner by a significant QTL on Chr 12 and several
suggestive loci on chromosomes 2, 4, and 17. The locus on Chr 12 is likely to be the
single primary factor responsible for differential weight loss following infection.
Interestingly, in a parallel study in which we have used survival as the key outcome
phenotype, we identified a highly significant QTL on Chr 5, with no contribution from
Chr 12.
Analysis of weight loss phenotypes over the course of infection yielded some
interesting findings. First, the cohort of BXD genotypes displayed a wide range of weight
loss kinetics that often did not always correlate with survival. For instance, BXD9 lost
weight more slowly than other strains, yet all of these animals succumbed to melioidosis
on or before day 4. In contrast, several genotypes that lost much more weight (and lost it
more rapidly) than BXD9 fell into the resistant category (100% survival). These findings
clearly showed that weight loss is not an ideal indicator for determining the ultimate fate
of Bp-infected mice. It seems likely that other infection models would display a similar
lack of correlation between weight loss kinetics and eventual mortality, a point that
should be shared with IACUC committees that require sacrifice of infected animals once
they reach an arbitrary percentage of weight loss.
Another interesting finding is the volatile nature of the set of three suggestive
QTLs detected only during the early stages of infection. These loci may be a sampling
artifact, but it is also possible that different phases of infection expose different gene loci.
The locus on chromosome 4 is only detected “acutely” at 24 hours post-infection.
Similarly, the two suggestive loci on day 2 are not even hinted at either on day 1 or day 3.
In contrast, the QTL that we detect on days 3 and 4 is consistent, and is also detected
when mapping with the weight loss “eigentrait” that summarizes weight loss across all
days. These findings suggest that weight loss following Bp infection may be a dynamic
phenotype that involves different host genes over the course of infection/disease.
Interestingly, a recently reported genome wide study of host response to H1N1 influenza
infection also identified multiple QTLs (different from those identified here) that appear
to control weight loss kinetics in a time-dependent fashion [73].
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Table 3-1. QTLMINER scores for candidate genes within the day 1 QTL interval
(Chr 4): Trait 16332.
Gene
Symbol

Mb

Chromosome 4
Car8
8.07

Ints8

11.13

Asph

9.38

Trp53in
p1

11.08

Plekhf2

10.92

2610301
B20Rik

10.80

Rbm35a

11.26

5730591
J02Rik

9.70

Ccne2

11.12

Runx1t1

13.67

Gene
Designation

carbonic
anhydrase 8
integrator
complex
subunit 8
aspartate-betahydroxylase

transformation
related protein
53 inducible
nuclear protein
1
pleckstrin
homology
domain
containing,
family F (with
FYVE
domain)
member 2
RIKEN cDNA
2610301B20
gene
RNA binding
motif protein
35A
RIKEN cDNA
5730591J02
gene
cyclin E2

runt-related
transcription
factor 1;
translocated
to, 1 (cyclin
D-related)

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels in
BXD
Mice

CisRegulated
in Lung

QTL
Miner
Score
(1-4)

phosphoinositidemediated signaling, onecarbon metabolic
process

184

9

Yes

4

35

4

Yes

4

oxidation reduction,
face morphogenesis,
palate development,
peptidyl-amino acid
modification, limb
morphogenesis, negative
regulation of cell
proliferation
pattern specification
process, peptidylaspartic acid
hydroxylation
apoptosis, cell cycle
arrest, response to
stress, induction of
apoptosis

47

35

Yes

4

18

1

No

3

phospholipid binding,
metal ion binding

10

1

No

3

unknown

17

3

Yes

3

mRNA processing,
RNA splicing,
regulation of RNA
splicing
unknown
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2

No

3

72

5

Yes

3

cell cycle, cell division,
regulation of cell cycle,
DNA replication
initiation
transcription, regulation
of transcription, DNAdependent fat cell
differentiation,
regulation of DNA
binding

4

2

No

2

8

8

No

2
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Table 3-1.

(Continued).

Gene
Symbol

Mb

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels in
BXD
Mice

CisRegulated
in Lung

Chd7

8.62

chromodomai
n helicase
DNA binding
protein 7

6

0

No

Tox

6.61

0

5

Yes

2

E13001
6E03Rik

11.49

thymocyte
selectionassociated
HMG box
gene
RIKEN cDNA
E130016E03
gene

transcription, chromatin
modification, regulation
of transcription,
chromatin assembly or
disassembly, adult
walking behavior, heart
morphogenesis, female
genitalia development,
camera-type eye
development
blood vessel
development, blood
circulation, adult heart
development,nose
development, embryonic
hindlimb
morphogenesis, palate
development, positive
regulation of
multicellular organism
growth, in utero
embryonic development,
sensory perception of
sound
ear morphogenesis,
inner ear morphogenesis
locomotory behavior
DNA binding, T-cell
devolopment

QTL
Miner
Score
(1-4)
2

28

3

No

2

Dpy19l4

11.19

dpy-19-like 4
(C. elegans)

18

3

unknown

2

1700123
O12Rik

10.44

6

14

No

2

RlBp1l
1

9.20

RIKEN cDNA
1700123O12
gene
retinaldehyde
binding
protein 1-like
1

DNA repair,
transcription, regulation
of transcription, doublestrand break repair via
homologous
recombination, response
to DNA damage
stimulus, response to
drug, response to
ionizing radiation
C-mannosylation of
tryptophan residues
unknown
transport

25

7

unknown

2
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Table 3-1.

(Continued).

Gene
Symbol

Mb

Gene
Designation

4930412
C18Rik

9.70

Rab2

8.46

2310030
N02Rik

10.98

1110037
F02Rik

11.41

Rbm12b

12.07

Gdf6

9.77

LOC242
317

10.37

A63003
4I12Rik

11.10

1700123
M08Rik

11.89

RIKEN cDNA
4930412C18
gene
RAB2,
member RAS
oncogene
family
RIKEN cDNA
2310030N02
gene
RIKEN cDNA
1110037F02
gene
RNA binding
motif protein
12B
growth
differentiation
factor 6
similar to Llactate
dehydrogenase
A chain
(LDH-A)
(LDH muscle
subunit)
(LDH-M)
RIKEN cDNA
A630034I12
gene
RIKEN cDNA
1700123M08
gene

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels in
BXD
Mice

CisRegulated
in Lung

unknown

80

5

unknown

QTL
Miner
Score
(1-4)
2

GDP binding, GTP
binding

5

12

unknown

2

unknown

7

1

unknown

2

RNA splicing, mRNA
processing

26

9

unknown

2

RNA binding,
nucleotide binding

5

0

No

1

growth, BMP signaling
pathway

1

0

No

1

unknown

0

1

unknown

1

unknown

0

2

unknown

1

unknown

0

1

unknown

1
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Table 3-2. QTLMINER scores for candidate genes within day 2 QTL intervals
(Chrs 2 and 17): Trait 16333.
Gene
Symbol

Mb

Chromosome 2
Lama5
179.91

Gene
Designation

laminin,
alpha 5

GtpBp5

179.81

GTP binding
protein 5

Psma7

179.77

OsBpl2

179.85

Ss18l1

179.78

Cdh4

179.18

proteasome
(prosome,
macropain)
subunit,
alpha type 7
oxysterol
binding
protein-like
2
synovial
sarcoma
translocation
gene on
chromosome
18-like 1
cadherin 4

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels
in
BXD
Mice

CisRegulated
in Lung

QTL
Miner
Score
(1-4)

cell adhesion, regulation
of cell migration,
regulation of cell
adhesion,regulation of
embryonic development
hair follicle development,
muscle organ development
lung development,
branching involved in
ureteric bud
morphogenesis, organ
morphogenesis, cilium
assembly
neural crest cell
migration,branching
morphogenesis of a
tube,morphogenesis of a
polarized epithelium,
regulation of cell
proliferation,
morphogenesis of
embryonic epithelium,
odontogenesis of dentinecontaining tooth
branching involved in
salivary gland
morphogenesis
ribosome maturation
process, GTPase

58

5

Yes

4

8

1

Yes

4

proteolysis involved in
cellular protein catabolic
process, ubiquitindependent protein
catabolic process
transport, lipid transport,
steroid metabolic process

2

0

Yes

3

8

5

No

3

transcription, chromatin
modification, regulation of
transcription, regulation of
transcription, DNAdependent
dendrite development
cell adhesion, axon
guidance, positive
regulation of axon
extension, heterophilic
cell-cell adhesion,
homophilic cell adhesion

18

0

Yes

3

14

57

No

2
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Table 3-2.
Gene
Symbol

(Continued).
Mb

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

Taf4a

179.65

transcription from RNA
polymerase II promoter,
ovarian follicle
development, regulation of
transcription from RNA
polymerase II promoter

Adrm1

179.91

TAF4A
RNA
polymerase
II, TATA
box binding
protein
(TBP)associated
factor
adhesion
regulating
molecule 1

Hrh3

179.83

histamine
receptor H 3

4930449
I21Rik

179.39

RIKEN
cDNA
4930449I21
gene

Chromosome 17
Pacrg
10.60

Park2 coregulated

CisRegulated
in Lung

3

InDels
in
BXD
Mice
0

No

QTL
Miner
Score
(1-4)
2

proteasomal ubiquitin
receptor, regulation of
deubiquitinating enzyme

9

0

No

2

G-protein coupled
receptor protein signaling
pathway, signal
transduction,negative
regulation of adenylate
cyclase activity, elevation
of cytosolic calcium ion
concentration, learning
memory, negative
regulation of glutamate
secretion, negative
regulation of gammaaminobutyric acid
secretion, regulation of
norepinephrine secretion,
negative regulation of
serotonin secretion
response to organic cyclic
substance, eating behavior
drinking behavior,
negative regulation of
blood pressure, positive
regulation of epithelial cell
proliferation, cognition
unknown

3

0

No

1

0

1

No

1

Functions within a
multiprotein E3 ubiquitin
ligase complex

36

19

Yes

4

29

Table 3-2.
Gene
Symbol

(Continued).
Mb

Gene
Designation

Qk

10.40

quaking

Pde10a

8.99

phosphodiest
erase 10A

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

vasculogenesis, cell
differentiation, transport,
regulation of translation,
multicellular organismal
development, RNA
splicing, mRNA transport,
mRNA processing, axon
ensheathment,
myelination, muscle cell
differentiation, long-chain
fatty acid biosynthetic
process
signal transduction, cAMP
catabolic process, cGMP
catabolic process

30

CisRegulated
in Lung

2

InDels
in
BXD
Mice
1

No

QTL
Miner
Score
(1-4)
3

8

10

No

2

Table 3-3. QTLMINER scores for candidate genes within the days 3-4 QTL
interval (Chr 12): Traits 16334 and 16335.
Gene
Symbol

Mb

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels
in
BXD
Mice

CisRegulated
in Lung

QTL
Miner
Score
(1-4)

83.36

signalinduced
proliferationassociated 1
like 1

3

7

Yes

4

Ttc9

82.73

38

3

Yes

4

Smoc1

82.13

extracellular matrix
organization, positive
regulation of cellsubstrate adhesion

18

15

No

3

Acot2

85.33

tetratricopepti
de repeat
domain 9
SPARC
related
modular
calcium
binding 1
acyl-CoA
thioesterase 2

regulation of synaptic
plasticity, regulation
of small GTPase
mediated signal
transduction,
regulation of dendrite
morphogenesis
protein folding

5

0

No

2

Psen1

85.03

lipid metabolic
process, acyl-CoA
metabolic process,
very-long-chain fatty
acid catabolic process
regulation of resting
membrane potential,
negative regulation of
neuron apoptosis,
protein maturation by
peptide bond cleavage,
regulation of synaptic
transmission,
glutamatergic
neurogenesis, skeletal
system
morphogenesis, T cell
activation during
immune response,
brain morphogenesis,
dorsal/ventral neural
tube patterning,
hemopoietic
progenitor cell
differentiation;
myeloid leukocyte
differentiation,
endoplasmic
reticulum, calcium ion
homeostasis, CajalRetzius cell
differentiation, T cell
receptor signaling
pathway, thymus
development, positive
regulation of apoptosis

0

1

No

2

Chromosome 12
Sipa1l1

presenilin 1
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Table 3-3.
Gene
Symbol

(Continued).
Mb

Gene
Designation

Biological
Processes/Functions

Rbm25

84.97

Nek9

86.64

apoptosis, RNA
splicing, mRNA
processing
cell cycle, cell
division, mitosis,
protein amino acid
phosphorylation

2410016O06R
ik

85.29

RNA binding
motif protein
25
NIMA (never
in mitosis
gene a)related
expressed
kinase 9
RIKEN
cDNA
2410016O06
gene

Zfyve1

84.89

Rgs6

83.72

Pcnx

82.96

Map3k9

82.83

zinc finger,
FYVE
domain
containing 1
regulator of
G-protein
signaling 6

pecanex
homolog
(Drosophila)
mitogenactivated
protein kinase
kinase kinase
9

CisRegulated
in Lung

0

InDels
in
BXD
Mice
1

No

QTL
Miner
Score
(1-4)
2

2

0

No

2

transcription,
oxidation reduction,
regulation of
transcription,
chromatin
remodeling,
ribosome biogenesis,
chromatin
modification,
negative regulation
of osteoblast,
differentiation,
negative regulation
of transcription,
DNA-dependent,
histone H3-K4
demethylation,
histone H3-K36
demethylation
biological process

1

0

No

2

1

0

No

2

signal transduction,
negative regulation
of signal
transduction,
intracellular
signaling cascade
G-protein coupled
receptor protein
signaling pathway
positive regulation of
neuron
differentiation
biological process

9

31

No

2

2

0

No

2

protein amino acid
phosphorylation, cell
death
positive regulation of
apoptosis

1

0

No

2

32

nsSNPs
(B6 vs.
D2)

Table 3-3.
Gene
Symbol

(Continued).
Mb

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels
in BXD
Mice

CisRegulated
in Lung

integrin-mediated
signaling pathway

3

0

No

QTL
Miner
Score
(1-4)
2

Adam4

82.52

Synj2Bp

82.59

a disintegrin
and
metallopepti
dase domain
4
synaptojanin
2 binding
protein

endocytosis,
cytoplasm
organization, protein
targeting, Rho
protein signal
transduction,
regulation of
endocytosis,
intracellular
distribution of
mitochondria
transport, vesiclemediated transport,
protein transport
intracellular protein
transport, regulated
secretory pathway,
vesicle targeting, to,
from or within Golgi

3

0

No

2

Tmed10

86.68

transmembra
ne emp24like
trafficking
protein 10
(yeast)

1

0

No

2

Ylpm1

86.34

YLP motif
containing 1

reduction of
telomerase activity
differentiation of
embryonic stem cells
transcription,
regulation of
transcription, DNAdependent, negative
regulation of
transcription from
RNA polymerase II
promoter

2

0

No

2

Jundm2

86.94

Jun
dimerization
protein 2

1

0

No

2

Rps6kl1

86.48

ribosomal
protein S6
kinase-like 1

protein amino acid
phosphorylation

0

1

No

1
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Table 3-3.
Gene
Symbol

(Continued).
Mb

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

Vsx2

85.91

visual system
homeobox 2

transcription, regulation
of transcription,
multicellular organismal
development, DNAdependent positive
regulation of cell
proliferation, positive
regulation of transcription
from RNA polymerase II
promoter, negative
regulation of cell
proliferation, cell fate
commitment, retina
morphogenesis in
camera-type eye, retinal
bipolar neuron
differentiation, cameratype eye development

Acot5

85.41

acyl-CoA
thioesterase 5

Acot3

85.39

acyl-CoA
thioesterase 3

Acot4

85.38

acyl-CoA
thioesterase 4

Tmem90a

86.02

transmembrane
protein 90a

acyl-CoA metabolic
process, lipid
metabolic process,
saturated
monocarboxylic acid
metabolic process,
long-chain fatty acid
metabolic process,
very-long-chain fatty
acid metabolic
process, unsaturated
monocarboxylic acid
metabolic process
lipid metabolic
process, unsaturated
monocarboxylic acid
metabolic process,
long-chain fatty acid
metabolic process,
very-long-chain fatty
acid metabolic
process, saturated
monocarboxylic acid
metabolic process,
acyl-CoA metabolic
process
acyl-CoA metabolic
process, succinyl-CoA
metabolic process,
lipid metabolic
process, short-chain
fatty acid metabolic
process, dicarboxylic
acid metabolic process
response to biotic
stimulus

34

CisRegulated
in Lung

0

InDels
in
BXD
Mice
1

No

QTL
Miner
Score
(1-4)
1

2

0

No

1

4

0

No

1

1

0

No

1

1

0

No

1

The H1N1 study identified a QTL on Chr 10 that was linked only with the day 1
weight loss trait, and they concluded that much of the weight loss was transient and
associated with the stress of anesthesia prior to intranasal instillation. Our findings
support a similar conclusion for the day 1 weight loss trait. Although the QTLs identified
in the two studies are on different chromosomes, this conclusion is feasible because our
studies utilized inhaled isoflurane for anesthesia, while the studies by Nedelko et. al. used
injectable anesthesia (ketamine/xylazine). Another stressor that could account for
variation of the weight loss trait could be introduction of liquid vehicle (PBS) into the
lungs during intranasal instillation. Again, the identification of loci on different
chromosomes (Chrs 4 and 10) in our and the Nedelko et. al. studies, respectively, is
feasible because instillation was performed with different volumes of vehicle (50μl vs.
20μl, respectively).
We used QTLminer to analyze these QTL intervals and to identify genes that are
promising positional and biological candidate genes. Three candidate genes with high
QTLminer scores were identified within the significant QTL on chromosome 12 that was
observed on days 3 and 4 post-infection. One of these genes (Sipa1l1) encodes a protein
that is thought to be involved in several processes that impact innate immunity: (1)
positive regulation of RAP2A GTPase activity, (2) reorganization of the actin
cytoskeleton and recruitment of DLG4 to F-actin, and (3) regulation of dendritic spine
morphogenesis. Ttc9 is a hormonally regulated gene in breast cancer cells and may play a
role in cancer cell invasion and metastasis [127]. The final candidate gene (Smoc1)
encodes a putative regulator of osteoblast differentiation in bone marrow stromal cells
[128] and plays a critical role in ocular and limb development in mice and humans
through the modulation of BMP signaling [129, 130]. The heritability of the day 3 and
day 4 weight loss traits approached 93%, indicating that these traits are likely to be
genetically controlled. Moreover, principal component analysis revealed that the QTL on
Chr 12 contributed >70% of the total weight loss variability in the cohort, indicating that
a gene(s) within this interval is the most important genetic factor in weight loss kinetics.
Although the loci that were identified on days 1 and 2 post-infection contribute
30% or less to weight loss, we also examined them for gene candidates. There were four
high value candidates associated with the day 1 Chr 4 locus. Car8 encodes a protein that
is designated as carbonic anhydrase VIII, despite its lack of carbonic anhydrase activity.
Mice carrying non-functional Car8 mutations suffer from neurological defects [131]. The
Asph gene is expressed from two promoters and undergoes extensive alternative splicing,
resulting in a set of aspartate beta-hydroxylases that have distinct functional properties.
The longest isoform hydroxylates aspartic acid or asparagine residues in the epidermal
growth factor-like domains of several proteins, including protein C, coagulation factors
VII, IX, and X, and the complement factors C1R and C1S. ASPH is also thought to play
an important role in calcium homeostasis [132]. Trp53inp1 encodes an antiproliferative
and proapoptotic protein (tumor protein p53-inducible nuclear protein 1) that is involved
in cell stress responses by acting as a dual regulator of transcription and autophagy [133135]. TRP53INP1 protein also reduces cell migration by regulating expression of
SPARC, a regulator of cell growth through interactions with the extracellular matrix and
cytokines. Inst8 encodes one component of a complex (integrator complex) that

35

associates with RNA polymerase II and is involved in the processing of small nuclear
RNAs [136]. It remains unclear how any of the candidate genes within the Chr 4 interval
might be involved in weight loss kinetics during the initial stages of melioidosis.
There were several high-scoring candidate genes from the suggestive QTLs that
were observed on day 2 post-infection. Lama5 (Chr 2) encodes a protein that is thought to
mediate the attachment, migration and organization of cells into tissues during embryonic
development. GtpBp5 (Chr 2) encodes a putative GTPase that may play a role in the
regulation of processes such as protein synthesis, nuclear transport, membrane
trafficking, and signal transduction [137, 138]. The gene product of Ss18l1 (Chr 2) is a
transcriptional activator that is required for calcium-dependent dendritic growth and
branching in cortical neurons. Psma7 (Chr 2) encodes a member of the peptidase T1A
family that functions as a 20S core alpha proteasome subunit and participates in
cytoplasmic protein degradation and recycling, while OsBpl2 encodes a member of the
oxysterol-binding protein family of intracellular lipid receptors, known as oxysterol
binding protein-like 2 [139]. Two of the high-priority candidate genes on chromosome
17, Park2 and Pacrg, share a bidirectional promoter and are co-regulated in various
tissues. Their gene products are involved in the degradation of misfolded or damaged
proteins as well as in autophagy and mitophagy, and have a strong association with the
development of Parkinson’s disease [140] [141, 142]. Interestingly, single nucleotide
polymorphisms of Park2 and Pacrg are also associated with leprosy susceptibility in the
Chinese population [143]. The other high scoring candidate gene on chromosome 17 was
Qk, a gene that encodes an RNA-binding protein that plays a central role in myelination;
dysfunction of this gene may result in myelin and/or oligodendrocyte dysfunction in
schizophrenia [144]. It is difficult to predict the role of any of these genes in weight loss
kinetics, but because the heritability of the Day 2 weight loss trait is approximately 87%
(compared to 68.8% for the day 1 weight loss trait), it is much more likely that genes
from one or both of these QTLs exert some control over weight loss during melioidosis.
Our findings indicate that weight loss kinetics during acute pneumonic Bp
infection is a heritable and dynamic trait that is controlled by several host loci in a time
dependent fashion. A significant QTL on Chr 12 (between 80 and 87Mb) appears to be
the most important genetic factor, while loci on chromosomes 2, 4, and 17 also contribute
to weight loss. The strongest candidate genes are involved in processes that could be
critical for immune processes, such as regulation of GTPase activity, reorganization of
actin cytoskeleton, hydroxylation of coagulation factors and complement components,
and autophagy. Several of the other strong candidates are involved in developmental
processes that include osteoblast differentiation, regulation of cell growth and migration,
tissue development during embryonic development, limb development, and myelination.
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CHAPTER 4. GENETICS OF DIFFERENTIAL SUSCEPTIBILITY TO
PNEUMONIC BURKHOLDERIA PSEUDOMALLEI INFECTION
INTRODUCTION
In humans, infection with Bp can cause a rapidly developing acute form of
melioidosis or there can be an extended latency period (that can last for many years)
before the patient becomes symptomatic. In fact, Bp infection has been described as the
“Vietnamese time bomb” due to reports that some US servicemen developed melioidosis
up to six decades after their exposure to the bacterium in Vietnam [26, 145-147]. Humans
and animals exhibit a broad range of clinical presentations following infection with Bp,
but the host factors that contribute to the different forms of melioidosis remain unclear.
Although no causal relationship has been determined, pre-existing host conditions in
humans (such as renal dysfunction, diabetes mellitus, and alcoholism) are considered to
be risk factors for the disease [7]. As previously mentioned, associations have been
demonstrated between the clinical presentation of melioidosis and either the host’s HLA
haplotype [49] or the allelic forms of some cytokine-related genes expressed by the host
[50]. These findings suggest that host genetic factors determine (at least in part) the
susceptibility of individual patients to the various clinical presentations of this disease.
The murine infection model has been used to establish the importance of host
genetic background on the progression of Bp infection, which is considered to be an
excellent model for both the acute and chronic forms of human melioidosis [56, 60, 125].
BALB/c [56, 60] and D2 [61] mice are known to be extremely susceptible to the acute
form of melioidosis, while B6 mice [56, 60] are relatively resistant to the acute form of
the disease and instead tend to develop disease that progresses at a much slower rate. In
this report, we have utilized a panel of BXD mice to perform genome-wide linkage
analysis to identify host genetic loci that correlate with the differential susceptibilities of
B6 and D2 parental strains to acute melioidosis.
RESULTS
Susceptibility of B6 and D2 Mice to Pneumonic Bp Infection
As previously mentioned in Chapter 3, our initial studies with a pneumonic
challenge model (intranasal instillation) confirmed the previously published observation
[55, 61] that B6 mice are more resistant than D2 mice to Bp infection. We performed
time course studies to kinetically evaluate the permissiveness of B6 vs. D2 mice to
replication of Bp in vivo. We found that following intranasal instillation of 50-100 CFU
of Bp strain 1026b, D2 mice experienced significantly higher (p0.001) bacterial burdens
in their lungs than B6 mice (see Figure 3-1A in Chapter 3). We also used survival as a
readout to examine the relative susceptibility of B6 vs. D2 mice to pneumonic Bp
infection. Following intranasal instillation with 50-100 CFU of Bp 1026b, we found that

37

D2 mice were significantly more susceptible to Bp infection than B6 mice (p0.0001) as
they succumbed to infection by day 4 post-infection, while B6 mice survived the
infection (see Figure 3-1B in Chapter 3). Subsequent studies showed that the same
results were obtained with challenge doses of up to 200 CFU/mouse (data not shown).

Susceptibility of BXD RI Mice to Pneumonic Bp Infection
To identify host genetic elements that are covariant with the variable
susceptibility of murine hosts to pneumonic Bp infection, we initiated forward genetics
studies with a cohort of BXD strains using survival of pneumonic infection as the
phenotypic readout. Groups of male mice from 32 BXD strains were challenged with 50100 CFU of Bp 1026b (from a diluted frozen stock) via intranasal instillation and then
monitored for survival. B6 and D2 mice were included in each of the 20 experiments that
were performed, and the D2 mice were always the last group to be challenged to ensure
the “potency” of the challenge stock throughout the instillation process. Strains that
succumbed to acute melioidosis where given a score of “0” and mice that survived the
challenge with Bp were given a score of “1”. We found that several of the BXD strains
were highly susceptible to Bp (similar to D2 mice), others were relatively resistant to Bp
(similar to B6 mice), and several strains displayed intermediate phenotypes
(Figure 4-1A).
Heritability of Survival and Time-to-Death
Our data indicate that there are significant differences observed amongst the
different BXD strains for survival and time-to-death. Since all mice used in this study
were bred and housed in the same environment, it is likely that the observed differences
in these phenotypes are mainly due to genetic variation. A heritability analysis
summarizes how much of the variation in a trait is due to variation in genetic factors (as
opposed to environmental or technical errors) and this value can range from 0 to 100%.
The heritability of our survival and time-to-death trait was 71%, indicating that these
traits are likely to be genetically controlled.
Identification of Host Genetic Loci that Influence Survival Following Pneumonic Bp
Infection
Whole-genome linkage analysis of the survival phenotype using this cohort of
animals revealed a significant QTL on chromosome 5 (genome-wide significance of
0.015, LRS of 24.1 with D alleles contributing to increased survival) encompassing a
region of approximately 12 megabases and a significant QTL on chromosome 7
(genome-wide significance of 0.017, LRS of 23.5 with D alleles contributing to increased
survival) encompassing a region of approximately 10 megabases that are both covariant
with differential susceptibility/resistance to acute pneumonic melioidosis (Figure 4-1B).
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Figure 4-1. Genome-wide linkage analysis of survival following pneumonic
challenge with Burkholderia pseudomallei.
A cohort of male mice, which included 32 BXD strains, was infected intranasally with
50-100 CFU of Burkholderia pseudomallei. Infected mice were monitored for survival
for up to 11 days post-infection and those that survived infection were given a value of
“1” while those that succumbed to infection received a value of “0”. Panel A: Log-Rank
plot showing the mean± SEM of the survival value for each strain. Panels B and C:
Standard and weighted interval mapping, respectively, was performed using the in silico
resources within GeneNetwork.org to identify genetic loci that correlated with survival.
The blue line indicates LRS scores across the entire genome. Thin red and green lines
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases
for each chromosome, and the y-axis represents the LRS score. Thick red and grey
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive
threshold (p<0.63), respectively.
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Intriguingly, these loci have an additive allele effect that does not correspond to
expectation based on parental strain survival (D2 low, B6 high). Weighted QTL analysis
of this dataset identified the loci on chromosomes 5 and 7 as highly significant QTLs
(genome-wide significances of 0.011 and 0.009 with LRS scores of 161.7 and 175.9,
respectively) (Figure 4-1C). The significant QTLs on chromosomes 5 and 7 were also
identified when we used time-to-death of this BXD cohort as a phenotype for QTL
analyses (Figure 4-2). It should be noted that further investigation of these two QTL
regions using composite interval mapping and haplotype analyses revealed chromosomes
5 and 7 are co-dependent because they exhibit the same pattern of inheritance. As a
result, the QTL peak on chromosome 7 is more than likely to be an artifact (discussed in
chapter 6).
Identification of Candidate Host Genes that May Contribute to Host
Susceptibility/Resistance Following Bp Infection
The significant QTLs on chromosomes 5 and 7 each encompass regions of
approximately 10-12 megabases that encode approximately 120 and 70 genes,
respectively. We analyzed each of these loci to identify specific candidate genes within
the QTL intervals whose function(s) might be important for the survival phenotype. For
these candidate gene searches, we considered peak height and bootstrap analyses to
define the QTL intervals (Figure 4-3). We then utilized the QTLminer tool [126] in
GeneNetwork to identify genes within the QTL that are most likely to contribute to host
susceptibility to pneumonic Bp infection. QTLminer scores genes on a scale of 0 to 4
based on the following criteria: (1) the gene has a mRNA expression value ≥8 in the
lungs in at least one of the expression databases provided on GeneNetwork, (2) the gene
is cis-regulated in lung, (3) the gene contains at least 1 nonsynonymous SNP between the
parental B6 and D2 mice, and (4) and the gene contains indels in BXD mice. The genes
within each QTL that had the highest QTLminer score are listed in Figure 4-3 and in
Table 4-1.
Identification of Candidate Genes from Expression Profiling Using RNA-Seq
Successful incorporation of RNA-Seq data with results of QTL mapping from an
AIL can significantly reduce the number of positional candidates within the QTL
region(s) [148]. We performed expression profiling on the lung tissue of 5 different BXD
RI strains (3 mice/strain) infected with Bp 1026b for 24 hours. The resistant BXD strains
used (BXD50 and BXD70) are the most resistant strains we have tested to date (100%
survival with better weight retention when compared to B6 mice). The susceptible BXD
strains used (BXD63, BXD09 and BXD27) had an average survival time of 4 days with
100% mortality (similar to D2 mice). Comparison of RNA expression between the
resistant and susceptible mice identified many genes whose expression differed
significantly. We used a stringent threshold of a ≥2-fold change and a p-value of ≤ 0.05
for our analyses. Clustering based on functional characteristics between the resistant and
susceptible strains revealed many of the upregulated genes in the resistant strains were
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Figure 4-2. Genome-wide linkage analysis of the time-to-death trait following
pneumonic challenge with Burkholderia pseudomallei.
A cohort of male mice, which included 32 BXD strains, was infected intranasally with
50-100 CFU of Burkholderia pseudomallei. Infected mice were monitored for survival
for up to 11 days post-infection. Mean survival time of each strain is shown in Panel A:
Log-Rank plot showing the mean± SEM of the survival time for each strain. Panel B:
Interval mapping was performed using the in silico resources within GeneNetwork.org to
identify genetic loci that correlated with time-to death. The blue line indicates LRS scores
across the entire genome. Thin red and green lines indicate that B6 or D2 alleles increase
trait values, respectively. The mouse chromosomes are identified in the upper x-axis, the
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively.
genes on chromosomes 5 and 7 that may have some influence of the host response to
pneumonic Bp infection.
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Figure 4-3. Detailed maps of QTLs contributing to survival and candidate genes
within these intervals.
Left hand panels: The critical intervals were identified based on bootstrap analysis
(frequencies of peak LRS indicated with yellow bars) and peak shapes. The density of
SNPs present in the BXD strains is indicated by orange chatter along the x-axis. The
multicolored chatter along the top of the graph represent the open reading frames within
the interval. The blue line indicates LRS scores across the entire genome. Thin red and
green lines indicate that B6 or D2 alleles increase trait values, respectively. The mouse
chromosomes are identified in the upper x-axis, the lower x-axis shows the physical map
in mega bases for each chromosome, and the y-axis represents the LRS score. Thick red
and grey horizontal lines indicate the genome-wide significance threshold (p<0.05) or
suggestive threshold (p<0.63), respectively. Right hand panels: Candidate genes within
each interval are indicated along with their LRS score and their relative expression levels
in normative tissues.
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Table 4-1. QTLMINER scores for candidate genes within the QTL interval for the
survival trait (Chrs 5 and 7): Trait 16330.
Gene
Symbol

Mb

Chromosome 5
Art3
92.76

Gene
Designation

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

InDels
in
BXD
Mice

CisRegulated
in Lung

QTL
Miner
Score
(1-4)

ADPribosyltransferas
e3
ankyrin repeat
domain 17

protein amino acid
ADP-ribosylation

103

10

Yes

4

endoderm
development

20

11

Yes

4

GTPase
activating
protein (SH3
domain) binding
protein 2
Nacylsphingosine
amidohydrolase
(acid
ceramidase)-like
annexin A3

transport, small
GTPase mediated
signal transduction,
mRNA transport

8

1

Yes

4

lipid metabolic
processes

54

4

Yes

4

positive regulation of
DNA metabolic
processes
protein amino acid
phosphorylation,
regulation of bone
mineralization
inflammatory
responses, immune
responses, cytokinecytokine receptor
interaction,
chemokine signaling
pathway, toll-like
receptor signaling
pathway
epidermal growth
factor receptor
signaling pathway,
positive regulation of
cell proliferation,
glial cell
proliferation, neuron
projection
development,
positive regulation of
phosphorylation,
negative regulation of
osteoblast
differentiation,
response to glucose,
ErbB signaling
pathway

7

8

Yes

4

6

6

Yes

4

27

4

Yes

3

6

0

Yes

3

Ankrd17

90.66

G3Bp2

92.48

Asahl

92.69

Anxa3

97.22

Bmp2k

97.43

BMP-2inducible kinase

Cxcl9

92.75

chemokine (CX-C motif)
ligand 9

Areg

91.57

amphiregulin
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Table 4-1.

(Continued).

Gene
Symbol

Mb

Cox18

90.64

Biological
Processes/Functions

nsSNPs
(B6 vs.
D2)

Cox18
cytochrome c
oxidase
assembly
homolog

protein insertion into
membrane

66.48

ubiquitin protein
ligase E3A

Atp10a

65.91

ATPase, class
V, type 10A

Tubgcp5

63.05

Nipa1

63.23

Nav2

56.21

tubulin, gamma
complex
associated
protein 5
non imprinted in
PraderWilli/Angelman
syndrome 1
homolog
neuron
navigator 2

protein modification
processes, protein
ubiquitination,
positive regulation of
transcription from
RNA polymerase II
promoter, prostate
gland growth,
ubiquitin-dependent
protein catabolic
processes, positive
regulation of
phosphoinositide 3kinase cascade,
sperm ent, Ubiquitin
mediated proteolysis
phospholipid
transport, metabolic
processes, ATP
biosynthetic
processes
microtubule
cytoskeleton
organization

Chromosome 7
Ube3a

Gene
Designation

CisRegulated
in Lung

15

InDels
in
BXD
Mice
0

Yes

QTL
Miner
Score
(1-4)
3

9

13

Yes

4

11

15

Yes

4

13

8

Yes

4

transport, ion
transport, magnesium
ion transport

3

2

Yes

4

neuronal
development, neurite
outgrowth

56

59

Yes

4
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involved in processes such as immune response, defense response, regulation of
apoptosis, and inflammatory response (Table A-2). The majority of the upregulated
genes in the susceptible strains were involved in processes such as vesicle-mediated
transport, membrane organization, defense response, and endocytosis (Table A-3).
DISCUSSION
It has been known for some time that distinct inbred strains of mice display a
range of susceptibility to Bp infection. In this study, we employed a panel of recombinant
inbred BXD genotypes to identify regions of the murine genome that are responsible for
variable susceptibility to this bacterial pathogen. Since our trait is more than likely
genetically controlled, we performed genome wide linkage analysis using survival and
time-to-death following pneumonic infection with Bp 1026b to identify host genes
involved in the differential progression of melioidosis. We identified two significant
QTLs, one on chromosome 5 and the other on chromosome 7 that appear to be involved
in the variability of susceptibility to pneumonic Bp infection. We utilized the in silico
tools in GeneNetwork and global transcription data to identify candidate genes within
each of these QTL intervals that are most likely to play a role in the outcome of Bp
infection.
Most of the high-priority candidate genes identified (using QTLminer) within the
QTL on chromosome 5 appear to have a role in immunological processes. For instance,
the cox18 gene encodes a mitochondrial inner membrane protein that is involved with
cytochrome C assembly. It is known that a mutation of Cox18 results in deficient
cytochrome C oxidase activity that, in turn, eliminates activation of cell surface receptors
involved in apoptosis [149], a process that is essential for limiting replication of some
intracellular bacterial pathogens [109, 150]. Another candidate gene in the interval,
G3Bp2, encodes GTPase activating protein-binding protein 2. This protein is known to
interact with IκBD and has been implicated in the regulation of NF-κB [151]. The NF-κB
family of transcription factors is a group of evolutionarily conserved proteins involved in
lymphoid organogenesis, development of immune cells [152] and the coordination of
many aspects of innate and adaptive immunity to infection. Cxcl9 encodes a chemokine
whose function(s) have not been clearly defined, but are likely to be important for T cell
trafficking [153]. Art3 is one of five genes that encode a family of arginine-specific ADPribosyltransferases, or ARTs. Arts 1 and 2 are known to play a role in the function of
immune lymphocytes [154, 155]. ADP-ribosyltransferase activity has also been detected
on the surface of both human neutrophils [156] and monocytes [157] and the activity of
these enzymes is elevated in response to LPS treatment. Ankrd17 encodes a protein
(ankyrin repeat protein 17) that participates in innate immunity by interacting with
several intracellular molecules (RIG-I, MDA5, and VISA) that have a role in sensing the
presence of diverse viral RNAs, resulting in positive regulation of RIG-I-like receptormediated immune signaling [158]. Anxa3 encodes a protein that is known to have a role
in bacterial phagocytosis [159], and as such is implicated as a component of the innate
immune response. Asahl encodes an N-acylsphingosine amidohydrolase that catalyzes the
synthesis and degradation of ceramide into sphingosine and fatty acid. Mutations in this
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gene have been associated with a lysosomal storage disorder known as Farber’s disease
[160]. This enzyme is involved in apoptosis pathways as well, but it is unclear whether it
is directly involved in innate immunity. Amphiregulin (Areg) is a member of the
epidermal growth factor family and has an important role in the immune response to
nematode infection [161]. Finally, Bmp2k (the gene that encodes BMP-2-inducible
kinase) is also found within this QTL. Bone morphogenic proteins (BMPs) have no
known role in immune responses, but they are known to play a key role in skeletal
development and patterning [162] and have been implicated in lung development, and
adult lung homeostasis [163].
Only one of the candidate genes with the highest correlation indices within the
QTL on chromosome 7 (Ube3a, Tubgcp5, Nipa1, and Nav2) have an obvious role in host
innate immune responses. Ube3a encodes E3 ubiquitin-protein ligase, part of the
ubiquitin protein degradation system [164]. Although this process is critical for antigen
presentation to T cells, it likely has no role in innate immune responses. Tubgcp5 encodes
a protein (gamma complex-associated protein 5) that has essential roles in mitotic spindle
formation [165, 166] and microtubule nucleation and organization [165, 167]. Nipa1
encodes a protein that plays a role in nervous system development and maintenance
[168], and may function as a receptor or magnesium transporter [169], and Nav2 encodes
neuron navigator 2, a protein involved in neuronal development, but that likely has no
direct role in innate immunity. However, Atp10a encodes a P-type cation transport
ATPase that could have an important role in disease susceptibility. In a recent
transcriptomic study designed to identify genetic markers that can differentiate between
individuals that experience either acute vs. latent Mycobacterium tuberculosis (MTB),
Atp10a was one of three genes (along with Cxcl10 and Tlr6) whose expression levels
were discriminatory. It remains to be determined whether Atp10a
expression/functionality is responsible for variable susceptibility to MTB.
We went further and cross-referenced candidate genes generated from QTLminer
with our RNA-Seq expression data. We checked for genes that fell within our suggestive
and/or significant QTL regions for our weight loss (chromosome 4, 7-11 mb,
chromosome 2, 179.25-180 mb, and chromosome 17, 9.5-11.5 mb) and survival
(chromosome 5, 85-98 mb and chromosome 7, 56- 67 mb). This analysis found a few
compelling genes that fell within two of our QTL intervals (chromosomes 5 and 7).
Genes that were significantly upregulated in the resistant strains include the closely
related interferon-gamma inducible genes, Cxcl9, Cxcl10, and Cxcl11, that encode the
chemokine (C-X-C motif) ligands 9, 10, and 11, respectively; and Ndn, which encodes
the protein necdin. These genes exhibited a Bp-infection state fold change of 10, 9, 24,
and 4, respectively. Specifically, in humans, Cxcl9 , Cxcl10 and Cxcl11 are inflammatory
chemokines that mediate the recruitment of T cells, natural killer cells and
monocytes/macrophages at the site of infection [170]. These chemokines exert their
effects through their cognate G-protein coupled receptor, CXCR3 [170, 171]. Ndn is
located in the Prader-Willi Syndrome deletion region and encodes a growth suppressor
(necdin) that facilitates the entry of the cell into cell cycle arrest and inhibits cell growth
[172]. Furthermore, necdin has been called a multi-functional protein with a potential role
in tumor suppression [173].
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Next, we organized these candidate genes into cis eQTLs and trans eQTLs based
on the genomic location of the gene of origin. Cis eQTLs map to the same genomic
location as the expressed gene [174] and therefore exerts a direct effect on its function.
Conversely, trans eQTLs also known as distant eQTLs, map far away from the location
of the expressed gene and therefore has a secondary effect on the trait [77]. Cxcl9, Cxcl11
and Ndn are all cis eQTLs and are high priority genes for future validation studies to
completely examine their role in the resistance and/or susceptibility to Bp infection.
We performed this same cross-reference analysis with genes that were
significantly upregulated in the susceptible strains and fell within all of our suggestive
and/or significant QTL regions. Similar to the previous analysis, this approach did not
identify any genes within the weight loss QTL intervals. However, there were five
candidate genes found within our survival QTLs (on chromosomes 5 and 7) when crossreferenced with our expression data. They include, Fam47e (family with sequence
similarity 47), whose function has yet to be confirmed, but some reports describe it as
having transcription cofactor activity [175]. Prdm8 (protein domain containing 8) which
may play a role in chromatin binding, cell morphology and cytoskeletal organization
[176]. Chrna7 encodes the neuronal acetylcholine receptor subunit alpha-7, a cholinergic
receptor that mediates fast signal transmission at synapses and is a member of a
superfamily of ligand-gated ion channels [177]. Interestingly, this gene is located in a
major susceptibility locus for juvenile myoclonic epilepsy [178] and is near a
chromosomal location involved in the genetic transmission of schizophrenia [179]. Other
genes include, Snrpa1, which encodes the small nuclear ribonuclearprotein polypeptide
that function in mRNA processing by binding to RNA and cell cycle regulators [180].
Finally, Tm2d3 encodes TM2 domain containing 3, which may have functional roles in
cell death or cell proliferation signalling cascades [181]. Chrna7 is the only cis eQTL
from this group of candidate genes identified from our expression data. Infection state
differences of these genes ranged from two- to sevenfold in the susceptible mice. In sum,
only ~5% of differentially expressed genes from our expression profiling data reside
within our survival/weight loss QTL regions. This observation calls into question the role
of the remaining differentially expressed genes corresponding to survival of Bp infection.
These genes may have a contributing role to survival during a Bp infection, although this
point is merely speculation. It would be interesting to evaluate whether we observe
alternate gene expression changes in various tissues and at different times points, which
may help in understanding some of the relationships in gene expression patterns during a
Bp infection.

47

CHAPTER 5. EFFICIENT INACTIVATION OF BURKHOLDERIA
PSEUDOMALLEI OR FRANCISELLA TULARENSIS IN INFECTED CELLS FOR
SAFE REMOVAL FROM BIOSAFETY LEVEL 3 CONTAINMENT
LABORATORIES*
CHAPTER SUMMARY
Working with infectious agents that require BSL-3 level containment offers many
challenges for researchers. BSL-3 containment laboratories are usually not equipped with
expensive specialty equipment that is needed for studies such as flow cytometric analysis,
microscopy, and proteomic analyses. Therefore, for most researchers that are working
with BSL-3 level infectious agents, removal of samples from BSL-3 labs for these types
of studies is necessary, and methods for complete and dependable inactivation of the
samples are required. In this report, we carried out a thorough characterization of the
effectiveness of paraformaldehyde fixation for inactivation of cell samples infected with
the intracellular bacterial agents Burkholderia pseudomallei (Bp) and Francisella
tularensis (Ft), both of which are Tier 1 select agent pathogens that require BSL-3
containment. We have demonstrated that cells infected with these pathogens are
completely inactivated via 5-minute treatment with 4% paraformaldehyde. Moreover, a
15-minute treatment with 2% paraformaldehyde completely sterilized both Bp- and Ftinfected cells. These studies also revealed that Bp is significantly more sensitive to
paraformaldehyde treatment than Ft. Our findings have clearly demonstrated that a 15minute treatment of Bp- or Ft-infected cells with 4% paraformaldehyde solution will
allow for safe removal of the cell samples from BSL-3 labs for downstream studies.
INTRODUCTION
Flow cytometry has become an integral tool for the evaluation of immune
responses to various cells during an infection with viral or bacterial agents. Due to the
expense of this type of equipment and the technical expertise required for proper
operation, flow cytometers/cell sorters are typically found in shared core facilities that
employ dedicated operators for analysis of a variety of sample types. This creates many
challenges for researchers working with agents requiring biosafety level 3 (BSL-3)
containment, since most core flow cytometry facilities are located in laboratories with
biosafety level 2 (BSL-2) containment capabilities. Additional factors such as
biosecurity play a role when the agents in use are considered select agents, and these
security procedures must be maintained until the samples are rendered noninfectious.
*Reprinted with permission. Emery, F.D., J.M. Stabenow, and M.A. Miller, Efficient
inactivation of Burkholderia pseudomallei or Francisella tularensis in infected cells for
safe removal from biosafety level 3 containment laboratories. Pathogens and disease,
2014. 71(2): p. 276-81.
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Removal of BSL-3 agents to a lower containment level laboratory requires
inactivation of the pathogen to allow for safe manipulation of the sample, and to ensure
that biosafety considerations are met for personnel working with these samples [182].
This is of particular concern when dealing with BSL-3 select agents destined for flow
cytometric analysis, where the potential for generation of aerosols exists. While
biosafety standards have been well described for work with unfixed cells for cell sorting
procedures, little guidance can be found for effective inactivation procedures for
potentially infectious flow cytometry samples [183, 184]. Previous studies have shown
that samples containing high titers of known viruses were resistant to standard
inactivation procedures [185, 186]. These findings have been cited by the International
Society for Analytical Cytology (ISAC), which cautions that fixation procedures must be
carefully performed to ensure complete inactivation of any potential infectious agents to
reduce the health risk to laboratory personnel [187, 188]. The ISAC also recommends
that if samples are fixed, “appropriate methods must be selected to reliably inactivate
potentially biohazardous agents,” yet no specific methods are recommended [187].
Most fixation procedures for flow cytometry include the use of paraformaldehyde
(PFA) solutions at concentrations varying from 1-4%. Commercially available fixation
buffers are typically comprised of a neutral pH-buffered saline solution with 4% (w/v)
PFA. These methods have been shown to provide effective fixation of lymphoid cells,
following immunofluorescent staining of surface markers or intracellular cytokines, that
is compatible with flow cytometric analysis (BD Technical Data Sheet, BD Cytofix TM).
However, the ability of these compounds to provide for inactivation of potentially
infectious microorganisms has been focused primarily on clinical samples with low levels
of organisms present, and the incubation time for complete inactivation of potentially
infectious agents has not been established. Here we evaluate the PFA concentration and
incubation time required to completely inactivate Francisella tularensis and
Burkholderia pseudomallei within infected cells. Both of these agents are classified as
Tier 1 select agents and require BSL-3 containment. We have validated the inactivation
kinetics required to demonstrate complete inactivation of these bacteria to allow for
removal of samples from a BSL-3 laboratory for flow cytometric analysis using BSL-2
containment practices.
MATERIALS AND METHODS
Collection and Differentiation of Murine Bone Marrow Cells
Bone marrow cells were obtained aseptically from femurs and tibias of 9-12 week
old C57BL/6J mice using previously described methods [189] and cryogenically stored at
-80˚C in freezing medium (DMEM [ScienceCell, Carlsbad, Ca.] with 50% FCS [Sigma
Chemical Co., St. Louis, MO] and 10% DMSO [Sigma Chemical Co., St. Louis, MO]).
Frozen bone marrow cells were thawed and differentiated into BMDMs using culture
conditions that were established previously [190]. Briefly, after thawing cells were
pelleted via centrifugation (200 x g for 5 minutes at RT˚), resuspended in 10 mL bone
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marrow differentiation media (D20/30: DMEM supplemented with 20% FBS, 30% L-929
conditioned medium [LCCM], penicillin/streptomycin [100U/mL and 100mg/mL,
respectively, Cellgro, Manassas, VA], 2mM L-glutamine [Cellgro, Manassas, VA] and
50mg/mL gentamycin [Sigma, St. Louis, MO]), and seeded in 100-mm-diameter tissue
culture dishes (BD Biosciences, San Jose, CA). The cultures were incubated at 37°C in a
5% CO2 atmosphere for four days and then10mL of fresh D20/30 was added and
incubated for an additional 3 days to allow cells to adhere to the petri dish. To harvest the
BMDM, culture media was removed via aspiration and 10mL of cold 0.53mM
EDTA/PBS was added to the plate and incubated at 37°C for 15 minutes. The BMDM
were detached by gently pipetting the PBS across the dish several times. The BMDM
cell suspension was pelleted via centrifugation (200 x g for 5 minutes at RT˚) then
resuspended in BMDM cultivation media (D10/5: DMEM supplemented with 10% FBS,
5% LCCM, 2mM L-glutamine). The cells were then counted using a Scepter 2.0
Handheld Automated Cell Counter (EMD Millipore, Billerica, MA).
Bacteria
Burkholderia pseudomallei, strain 1026b (Bp) was obtained from Biodefense and
Emerging Infections Research Resources Repository (BEI Resources, Manassas, VA)
and Francisella tularensis tularensis, Schu S4 strain (Ft) was obtained from the Centers
for Disease Control and Prevention (CDC, Atlanta, GA). Overnight cultures of both
bacterial agents were prepared and used to inoculate fresh media. Once the bacteria
reached log-phase growth, they were pelleted by centrifugation, resuspended in the
appropriate media (see below) supplemented with 20% glycerol, aliquoted
(approximately 100μl/tube), and stored cryogenically at -80˚C. Bp was cultured in
unmodified LB broth and Ft was cultured in modified Mueller Hinton broth (MMH broth
supplemented with 10 g/L tryptone, 0.1% glucose, 0.025% ferrous pyrophosphate, 0.1%
L-cysteine, and 2.5% calf serum). Enumeration of these frozen stocks was performed by
dilution plating as described below. All work with these two bacterial agents was
performed under BSL-3 containment using standard operating procedures that were
reviewed and approved by the University of Tennessee Health Science Center (UTHSC)
Institutional Biosafety Committee (IBC). All BSL-3 laboratories in the RBL are
registered with the select agent Program and all of the work with the select agents was
done in a Centers for Disease Control (CDC)-approved facility (UTHSC Regional
Biocontainment Laboratory, CDC Registration Number: C20010616-1230).
Infection of Cells with Bp or Ft
BMDM were seeded into a 150-mm-diameter non-tissue culture dishes (Sarstedt,
Newton, NC) at a density of approximately 5 x 10e7 cells per plate and the bacteria
(thawed from frozen stocks and diluted) were added to each plate at an MOI of 100. Cell
cultures were allowed to incubate for approximately 12-15 hours after infection. After the
incubation period, the media was carefully aspirated from the cell monolayers and 10mL
of 0.53mM EDTA/PBS was added to each petri dish and allowed to incubate at 37°C for
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15 minutes. The macrophages were then detached by gently pipetting across the dish
several times. The infected cells were pelleted via centrifugation (200x g for 5 min @
RT˚), washed twice with DMEM-20 (DMEM supplemented with 20% FBS), and then
washed in culture medium containing kanamycin to kill remaining extracellular bacteria.
Cells were washed two additional times with PBS. The cells were then resuspended in 10
mL BD-Staining Buffer and then the cells were enumerated using a Scepter Handheld
Automated Cell Counter.
Fixation of Infected Cells
Bp- or Ft-infected cells were distributed into Eppendorf® tubes at approximately
1X10 cells/tube. The cells were pelleted via centrifugation (300x g at 4°C for 5 min) and
then supernatant was aspirated. Cells were then treated with 250μl BD-Cytofix Fixation
Buffer (Cytofix, BD Biosciences, cat.no. 554655, San Jose, CA) in undiluted form
(4.21% PFA solution), diluted 1:2 (2.1% PFA solution), diluted 1:4 (1% PFA solution),
or diluted 1:8 (0.5% PFA solution) and incubated for the indicated periods of time.
Dilutions of Cytofix were performed using BD Pharmingen Stain Buffer (Stain Buffer,
BD Biosciences, cat.no. 554655, San Jose, CA). Following the fixation incubation period,
the total volume of each sample was increased to 1 ml by addition of Stain Buffer, the
cells were pelleted via centrifugation (200 x g for 5 min at RT˚), supernatant was
aspirated, and the cells were resuspended in 1 ml of Stain Buffer.
6

Enumeration of Bacteria
At each of the indicated time points following Cytofix treatment, suspensions of
Bp- or Ft-infected cells that had been treated with Cytofix were subjected to dilution
plating, as previously described [108, 109], to enumerate the remaining viable Bp or Ft in
the sample. Briefly, the cell suspensions were plated in duplicate (100 μl of the fixed cell
preparation per plate) on either LB agar (Bp) or BHI agar (Ft) plates using an Eddy Jet
spiral plater (Neutec Group, Inc., Farmingdale, NY). Plates were incubated at 37˚C in a
static incubator for 24-48 hours and then colonies were counted using a Flash & Go
automated colony counter (Neutec Group, Inc., Farmingdale, NY) to determine the
bacterial burdens (CFU/mL).
RESULTS
To evaluate the ability of PFA to kill the intracellular bacterial pathogens
Burkholderia pseudomallei (Bp) strain 1026b and Francisella tularensis tularensis (Ft)
strain Schu S4 during fixation of infected cells, we performed time course studies in
which infected murine macrophages were treated with a range of concentrations of
paraformaldehyde solution (0.5-4%). Murine BMDMs were infected with each of the
pathogens at an MOI of 100 and cultured for 12-15 hrs to allow bacterial replication in
infected cells. After the cells were harvested, washed and enumerated, they were
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distributed into O-ringed centrifuge tubes (5 x 105 cells/tube) and pelleted via
centrifugation, supernatant aspirated away, and then the cells were resuspended in PFA
solution (0.5, 1.0, 2.1, or 4.21%). Dilution plating was performed at each treatment time
point (1, 5, 10, 15, 30, and 45 minutes as well as 1, 4, 8, and 24 hrs) to determine how
many viable bacteria remained in each fixed cell sample (Table 5-1 and Table 5-2). A 5minute treatment with BD-Cytofix (4.21% paraformaldehyde) killed all Bp
(Figure 5-1A) and Ft (Figure 5-1B), while 2.1% PFA treatment required 15 minutes to
completely sterilize the infected cell samples. Treatment with 1% or 0.5%
paraformaldehyde failed to completely sterilize infected cell samples even after a 24-hour
treatment period (Figure 5-1, Table 5-1 and Table 5-2).
Because the lower detection limit of the dilution plating method is approximately
20 CFU, we performed parallel experiments in which PFA-treated samples of infected
cells were added to 10 mL of broth culture medium (LB broth for Bp-infected cell
cultures and MH broth for Ft-infected cells) and incubated at 37˚C for 72 hours in a
shaking incubator. Optical density readings (OD@ 600nm) taken prior to and following
incubation to confirm that treatment for 5 minutes (or more) with 4% PFA or for 15
minutes (or more) with 2% PFA completely sterilized samples of Bp- or Ft-infected cells
(data not shown).
Analysis of the data generated for the 1% and 2.1% paraformaldehyde treatment
groups revealed that Bp is significantly more sensitive to paraformaldehyde treatment
than Ft (Figure 5-2). Over the treatment time course, the burden of viable Bp following
treatment with 1% and 2.1% paraformaldehyde solution was significantly lower than that
of Ft (p<0.0001 and p<0.0039, respectively). Moreover, although the reduction of viable
Ft was slightly greater than that of Bp following 15 minute treatment with 0.5%
paraformaldehyde, Bp was much more sensitive to treatment with higher concentrations
of paraformaldehyde solution (Table 5-3 and Table 5-4). For instance, a 15-minute
treatment with 1% paraformaldehyde resulted in a 6.6±1.72-fold reduction of viable Bp
numbers compared to only a 0.97±0.22 fold reduction of viable Ft. A 10-minute
treatment with 2.1% paraformaldehyde resulted in a 260.6±149.8-fold reduction of viable
Bp but only a 4.57±0.69-fold reduction of viable Ft, while a 1-minute treatment with
4.21% paraformaldehyde solution resulted in a 1555±865.7-fold reduction of viable Bp
numbers but only a 35.2±5.01-fold reduction of viable Ft numbers
(Table 5-3 and Table 5-4).
DISCUSSION
The BMBL clearly states that removal of research samples from BSL-3
containment for downstream studies (e.g. flow cytometric analysis, microscopy,
proteomic analyses, etc.) at lower biosafety levels requires reliable standard operating
procedures (SOPs) for complete infectious agent inactivation [191]. Although one could
reasonably assume that standard fixation or other inactivation procedures involving
various chemical agents would effectively inactivate most organisms, validation of the
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Table 5-1. Number of Burkholderia pseudomallei following paraformaldehyde
fixation of infected cell samples (1st 15 minutes of timecourse).
Treatment

1 Minute

5 Minutes

10 Minutes

15 Minutes

Untreated

119,333±14,224

113,333±5,686

99,567±2,676

94,700±985

0.5% PFA

91,900±7,539

84,800±200

81,267±2,098

79,233±3,355

1.0% PFA

52,967±3,742

37,967±4,438

35,133±4,329

12,900±2,946

2.1% PFA

42,667±907

12,230±8,128

538±419

0

4.2% PFA

89±33

0

0

0

PFA- paraformaldehyde

Table 5-2. Number of Francisella tularensis following paraformaldehyde fixation
of infected cell samples (1st 15 minutes of timecourse).
Treatment

1 Minute

5 Minutes

10 Minutes

15 Minutes

Untreated

4,437±325

4,290±251

4,433±125

4,517±278

0.5% PFA

4,290±251

4,320±375

3,663±134

3,483±672

1.0% PFA

2,783±50

1,940±251

1,810±26

1,753±57

2.1% PFA

1,983±533

1,427±93

890±15

0

4.2% PFA

141±32

0

0

0

PFA- paraformaldehyde
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Figure 5-1. Paraformaldehyde fixation conditions for killing of Burkholderia
pseudomallei and Francisella tularensis Schu S4 in infected cell samples.
Murine BMDMs infected with (Panel A) Burkholderia pseudomallei 1026b or (Panel B)
Francisella tularensis Schu S4 (5 x 106 cells/sample) were treated with the indicated
concentrations of paraformaldehyde for either 1, 5, 10, 15, 30, or 45 min and 1, 4, 8, and
24 hrs. At the end of the treatment period live bacteria were enumerated by dilution
plating. All data points represent the mean ± SEM of triplicate samples. Statistical
analysis was performed using a 2-way ANOVA and revealed that each of the PFA
treatments resulted in significant reduction of viable bacteria compared to untreated
controls (*** indicates p<0.001). The results shown are representative of three separate
experiments of similar design.
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Figure 5-2. Burkholderia psuedomallei is more sensitive than Francisella tularensis
to paraformaldehyde treatment.
Murine BMDMs infected with either B. pseudomallei or F. tularensis were treated with
the indicated concentrations of paraformaldehyde for either 1, 5, 10, 15, 30, or 45 min
and 1, 4, 8, and 24 hrs and then surviving bacteria were enumerated via dilution plating.
Data points represent the percentage of the starting number of CFU (untreated control
sample at that time point) that survived paraformaldehyde treatment and are presented as
the mean ± SEM of results with triplicate samples. Statistical analysis was performed
using a 2-way ANOVA and the indicated p-values reflect differences attributable to the
bacterium over the time course. Bonferroni posttests were also performed and significant
differences at each time point are indicated (*** indicates p<0.001). The results shown
are representative of three separate experiments of similar design.
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Table 5-3. Fold reduction of viable Burkholderia pseudomallei following
paraformaldehyde fixation of infected cell samples.
Treatment

1 Minute

5 Minutes

10 Minutes

15 Minutes

0.5% PFA

0.31±0.023

0.34±0.07

0.23±0.04

0.20±0.06

1.0% PFA

1.27±0.41

2.0±0.27

1.87±0.39

6.60±1.72

2.1% PFA

1.80±0.39

15.95±17.4

260.6±149.8

-

4.2% PFA

1555±865.7

-

-

-

PFA- paraformaldehyde

Table 5-4. Fold reduction of viable Francisella tularensis following
paraformaldehyde fixation of infected cell samples.
Treatment

1 Minute

5 Minutes

10 Minutes

15 Minutes

0.5% PFA

0.04±0.08

0.25±0.11

0.35±0.05

0.38±0.06

1.0% PFA

0.34±0.07

0.50±0.13

0.9±0.24

0.97±0.22

2.1% PFA

0.89±0.37

1.62±0.32

4.57±0.69

-

4.2% PFA

35.2±5.01

-

-

-

PFA- paraformaldehyde
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method is required with each infectious agent to satisfy these requirements. Moreover,
the selected method for deactivation must also be compatible with the downstream
analyses that will be performed on the inactivated sample. The use of published
inactivation methods must also be validated for each laboratory to ensure that the
procedures are followed correctly and complete inactivation can be achieved. The lack of
standardized protocols, including the kinetics of the methods, is problematic to
researchers working with BSL-3 agents and often requires development of methods that
meet the inactivation requirement while maintaining the integrity of the sample matrix for
subsequent analysis.
There are a variety of published studies that detail inactivation techniques for
Francisella tularensis. A study by Clemens and associates described the use of 4% PFA
in PBS overnight as an effective treatment for inactivation of Ft [192]. A different group
successfully utilized three different treatments (2% PFA for 1 hr, heat-inactivation at
60˚C for 16 hrs, or UV irradiation [7,500μJ/cm3 at RT˚]) to inactivate Ft [193]. Other
published studies reported that Ft is susceptible to heat-inactivation [194, 195] or that
inanimate surfaces contaminated with Ft can be sterilized by a combination of 10%
bleach treatment followed by 70% ethanol [196]. However, in each of these reports the
inactivation treatment was performed on bacteria alone, not on infected cells. Moreover,
among these inactivation methods, only PFA treatment is compatible with any of the
potential downstream analyses of infected cells. There is one published report that
described inactivation of Ft-infected cells using 3-8 % PFA treatment for 30 minutes
[197]. However, this paper does not contain any primary data related to the efficacy of
PFA inactivation, but instead only cites guidance from a 2006 CDC website report that is
no longer available.
There is also a paucity of published information relating to the inactivation of
Burkholderia pseudomallei. One published study showed that Bp in liquid samples could
be inactivated by treatment with a combination of pH, heat, and salinity [198]. Another
report revealed that Bp on environmental surfaces could be inactivated by treatment for
15 minutes with 6% PFA [199]. O’Connell and colleagues have published studies
designed to evaluate the effectiveness of chlorine-based disinfection (in water treatment
systems) for inactivation of Bp [200]. One of the most interesting findings in this report
related to the significant variability observed in the sensitivity of different Bp strains to
chlorine-based disinfection. These findings reinforced the idea that inactivation methods
should be validated for each infectious agent. We have been unable to find any published
studies that define inactivation parameters for Bp-infected cells that would be compatible
with downstream flow cytometric analysis.
The findings provided in this report are the first that clearly establish a procedure
that can be used to reliably and completely disinfect mammalian cells that have been
infected with the BSL-3 agents Ft and Bp, allowing for their removal from BSL-3
containment for downstream flow cytometric analyses using BSL-2 practices.
Paraformaldehyde treatment was chosen for the current studies because: (1) is the most
commonly used fixation treatment for flow cytometry samples, (2) it is known to have
negligible effects on fluorescence properties or forward scatter/side scatter characteristics
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of antibody labeled cells (Lal, et al., 1988), and (3) because there are commercial
sourcesof paraformaldehyde solutions that are designed specifically for fixation of cells
for flow cytometric analysis. Here we report that fixation for 5 minutes with a 4.21%
PFA solution is capable of complete sterilization of cell suspensions that have been
infected with either Ft or Bp. Moreover, a 15-minute treatment of Ft or Bp-infected cells
with a 2.1% PFA solution results in complete inactivation of the sample. Our findings
also indicated that treatment of either Ft- or Bp-infected cells with concentrations of PFA
that are lower than 2.1% (1% and 0.5 %) is likely to result in incomplete disinfection of
the samples. Based on these findings, we conclude that a 15 minute treatment of Ft- or
Bp-infected mammalian cells with 4.21% paraformaldehyde is an appropriate SOP for
inactivation of these two infectious agents, allowing for removal of fixed cells samples
from BSL-3 containment. Interestingly, we also found that Bp is significantly more
sensitive than Ft to PFA treatment. Although this finding did not impact the
establishment of the inactivation SOP, it did provide further evidence that infectious
agents display a range of sensitivities to chemical inactivation, underscoring the need for
independent testing and validation of inactivation SOPs for each agent. It is important to
note that these studies were performed exclusively on single cell suspensions of Bp or Ft
infected cells. It is likely that sterilization of Bp or Ft-infected tissues (that have not been
homogenized into single cell suspensions) would require longer exposure times than
those described in this report.
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CHAPTER 6.

DISCUSSION AND CONCLUSIONS
DISCUSSION

Bp is the cause of the frequently fatal infectious disease melioidosis. Little is
known about the influence of specific genes or genetic backgrounds in humans that
contribute to the susceptibility or resistance to Bp infections. Therefore, the identification
of key host genetic factors that control resistance or susceptibility to Bp is of much
importance. For these studies, we used a forward genetics approach to identify genomic
regions influencing infection-state phenotypes seen during a Bp infection. The results
from our studies demonstrate that the BXD RI strain panel and the GeneNetwork
Database are powerful genetic resources for analyzing the differential susceptibility to a
Bp infection. It has shown to be an efficient methodology which to examine infectious
disease susceptibility genes in a host utilizing an expanded set of RI strains. To our
knowledge, this study is the first report that uses a forward genetics approach to discover
genes that underlie resistance and/or susceptibility to this pathogen.
Our data indicate that genetic regulation of survival, time-to-death and weight loss
during a Bp infection is a complex phenomenon, whereby many genes exert their effects
on these traits. We observed significant differences in survival, time-to-death and weight
loss kinetics in the parental mice and across the different BXD strains following
pneumonic infection with Bp 1026b. This observed variability was expected based on the
genetic diversity of the parental mice and the BXD strain family. We hypothesize that the
observed differences in weight loss kinetics and survival amongst these strains can be
attributed to the genetic variation resulting in varying levels of qualitative and
quantitative profiles of the host defense. Furthermore, our heritability analyses for these
phenotypes indicate there is a major influence of genetic background to these traits.
Genome wide linkage analysis using these phenotypes identified several host loci
associated with the observed differential response to Bp, and it is apparent that these traits
are likely controlled by several loci encompassing many genes. According to our linkage
analysis, weight retention during a Bp infection is controlled by QTLs on chromosomes
2, 4, 12, and 17 in a time-dependent manner. This indicates that host loci within these
QTLs may be important for the host response in a transient and dynamic fashion during
melioidosis. However, a principle component analysis for weight loss at all days supports
a single chromosomal locus on chromosome 12 that accounts for >70% of the total
weight loss variability in the cohort. This means that loci identified on days 1 and 2
contribute 30% or less to the variation in weight loss kinetics indicating chromosome 12
is likely to be the single primary factor responsible for differential weight loss following
Bp infection. Interestingly, a recently reported genome wide study of host response to
H1N1 influenza infection also identified multiple QTLs (different from those identified
here) that appear to control weight loss kinetics in a time-dependent fashion [73]. This
study concluded that much of the initial weight loss was transient and associated with the
stress of anesthesia prior to intranasal instillation. Meanwhile, our genome wide linkage
analysis of survival (and time-to-death) generated two significant QTLs, one on
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chromosome 5 and the other on chromosome 7. It is worth noting that the lack of overlap
in loci contributing to survival compared to weight loss kinetics suggested that the weight
loss and survival traits are independently controlled. A network diagram generated using
the Network graphing feature of GeneNetwork confirmed that there was little correlation
between weight loss kinetics and either the survival or time-to-death phenotypes
(Figure 6-1).
The in silico tools in GeneNetwork allowed us to identify candidate genes within
the six previously identified QTL intervals that may be casual for resistance or
susceptibility to a Bp infection. In total, there are 335 positional candidate genes located
within these intervals. We were able to narrow down the total number of genes using
QTLminer to 46 high scoring (score of 3 or 4) candidates using additional information
such as normal gene expression levels in target organs, cis-regulation of the gene in the
lung and number of nonsynonymous SNPs or indels between the parental B6 and D2
genotypes. High scoring candidate genes within these intervals are involved in a wide
range of pathways that could be important for mounting an effective immune response
including, calcium homeostasis, cell stress responses, protein degradation and recycling,
extracellular matrix and actin reorganization, apoptosis, bacterial phagocytosis, immune
cell recruitment, tissue repair, lung homeostasis, cell cycle regulation and nervous system
development.
It has been suggested that variation in gene expression is an important contributor
to the genetic architecture of complex traits [148]. To get a glimpse into the infectionstate gene regulation that may contribute to increased or decreased survival during a Bp
infection, we performed host transcriptomic profiling using RNA-seq on the lung tissue
of a small cohort of resistant (BXD -50, -70) and susceptible (BXD -09, -63, -70) BXD
strains infected with Bp 1026b for 24 hours. This analysis revealed a very large number
of host genes that were upregulated in the resistant or susceptible strains during a Bp
infection. A gene ontology analysis provided insight into the common themes and
biological significance of this large pool of data. Analysis outputs consistently
demonstrated that the early host response in resistant strains, enriched for genes involved
in the immediate immune responses, which include response to IFN-gamma, leukocyte
activation, response to cytokine, and induction of apoptosis. The molecular function of
the majority of genes upregulated in the resistant strains were involved in binding, which
included antigen binding, chemokine receptor binding, and MHC class 1 and 1b protein
binding. This cluster of genes significantly upregulated in the resistant strains represent a
group of genes designated as “common host immune response”, and might signify a
general “alarm signal” for inflammatory infections [201]. Based on the function of genes
upregulated in the resistant strains we can infer that these genes allow activation of
defense programs and control of intracellular bacterial replication. Meanwhile, the early
host response in the susceptible strains enriched for genes involved in a variety of
processes including vesicle-mediated transport, membrane organization, defense response
and phagocytosis. Interestingly, there were genes also upregulated in the susceptible
strains 24 hours post-infection that function in a response to hypoxia, which could be
associated with the stress of anesthesia prior to intranasal installation. In fact, the timing
of this transcript increase also correlates to the appearance of the transient weight loss
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Figure 6-1. Correlation network for the survival, time-to-death, and weight loss
phenotypes following pneumonic B. pseudomallei infection.
The color of the lines connecting the B. pseudomallei disease-state traits indicate the
following correlation indices: red line / 0.7 to 1.0, orange line / 0.5 to 0.7, green line / 0.5 to -0.7, and blue line / -0.7 to -1.0.
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QTLs that we hypothesize may have been a result of the effects of anesthesia prior to the
Bp infection, similar to observations seen in the previously mentioned H1N1 study by
Nedelko et. al. [73]. There were also a large number of genes that function in vesiclemediated transport, which could function in many pathways including pathways that
modulate the host defense response. Moreover, seeing as though Bp enters the host cell in
a vesicle (endosome), these genes can also be implicated in increasing the permissiveness
of Bp replication in establishing an intracellular colonization niche since our previous
studies have illustrated that overwhelming bacterial loads are typical in the susceptible
parental strain (D2).
We went a step further and integrated the results of our RNA-Seq data with
results from our QTL mapping studies. We mined this data to only incorporate genes that
fell within any of our significant/suggestive QTL intervals. Using this approach, we were
able to reduce the number of candidates from 46 genes residing throughout six QTL
regions, to 10 high priority candidate genes on two QTLs (Chrs. 5 and 7) that were
differentially expressed between the susceptible and resistant strains. Most notably, this
analysis revealed a cluster of closely related interferon-gamma inducible genes, Cxcl9,
Cxcl10, and Cxcl11, that encode the chemokine (C-X-C motif) ligands 9, 10, and 11,
respectively and Ndn, which encodes the protein necdin (cell growth suppressor), all
which were significantly up regulated in the resistant strains. Other genes generated from
this analysis include Fam47e (family with sequence similarity 47), Prdm8 (protein
domain containing 8), Chrna7 (neuronal acetylcholine receptor subunit alpha-7), Snrpa1
(small nuclear ribonuclearprotein polypeptide), Tm2d3 (TM2 domain containing 3), and
Gm20457 (not yet characterized), which were all significantly upregulated in the
susceptible strains. These genes were further narrowed down to 4 potential candidate
genes based on the genomic location of the gene of origin (cis vs. trans eQTLs). Cxcl9,
Cxcl11, Ndn, and Chrna7 are all cis eQTLs that map to the same location as the
expressed gene and therefore exert a direct effect on its function. Functional studies
should commence with these genes as cis eQTLs generally have strong effect sizes and it
is easier to validate and interpret their affect on the trait [202] when compared to trans
eQTLs. Collectively, these results provided additional leverage for prioritization of
candidate genes for further interrogation.
The CXCL cluster of genes within our significant QTL region on chromosome 5
is of particular interest based on their known biological function and their obvious role in
immunity. Cxcl9 [also known as MIG, (monokine-induced by IFN-gamma)] and Cxcl11
[I-TAC, (T cell alpha chemoattractant)] are interferon-gamma inducible chemokines that
play a role in orchestrating immune cell accumulation (T cells, natural killer cells, and
monocytes/macrophages) and activation during an inflammatory response [203]. They
function through receptor dependent interactions through their cognate G-protein coupled
receptor CXCR3 [170, 203]. Previous studies have illustrated that neutralization of these
chemokines increases host susceptibility, thus the results of our gene expression profiling
suggest that high expression of Cxcl9 and -11 is associated with increased survival since
both are highly expressed in the resistant strains with an infection-state increase of 10 and
24, respectively. Future experiments would incorporate functional studies to validate
these candidate genes and explore their specific role during a Bp infection. For instance,
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we could use many traditional techniques such as Reverse-Transcriptase PCR (RT-PCR),
Real-time PCR (qPCR), ELISA, and RNA silencing, as previously described [47].
Specifically, infection-state expression levels of the candidate genes, can be measured via
RT-PCR and qPCR and differential protein expression can be measured by ELISA (or
western blotting). Another ideal approach would be to use knockout mice or dampen the
expression of the candidate genes using techniques such as RNA silencing in cells or
animals that express a functional form of the gene. In addition, the use of congenic strains
would be a valuable resource in analyzing our complex traits [204]. Congenic mice are
genetically engineered to carry a targeted mutation where a small portion of the donor
(mouse) genome is placed on a recipient mouse strain, allowing a defined chromosomal
region to be assayed. In using these molecular techniques and others, we can begin to
identify the functional roles of candidate genes that are responsible for observed
differential infection-state phenotypes in mice during a Bp infection.
In conclusion, there have been a number of studies that have identified host loci
that are covariant with susceptibility to viral, bacterial, and even parasitic infectious
agents. No clear pattern has emerged from these studies, and in fact, collectively their
findings indicate that host-pathogen interactions are extremely complex. Some of these
studies have identified single host loci that are responsible for disease susceptibility,
while others have determined that susceptibility to disease involves multiple host loci.
For instance, it has been documented that a single gene (Scl2) controls the predisposition
for development of cutaneous lesions following infection with Leishmania mexicana
[115]. It has also been shown that susceptibility to murine cytomegalovirus is controlled
by a single host loci that encodes an NK cell activating receptor [118, 119] and that a
single gene (Car2) serves as the susceptibility locus for Theiler's virus-induced
demyelinating disease [120]. In contrast, similar studies have revealed that susceptibility
to influenza virus infection is a multigenic trait, and that different arrays of host loci
control susceptibility to distinct strains of influenza [73, 123]. Studies of susceptibility to
bacterial pathogens have also yielded divergent results. A set of studies by Miyairi and
associates revealed that susceptibility to Chlamydia psittaci is a simple trait that is
controlled by a single host locus that encodes p47 GTPases [74, 100]. Another study
revealed that differential susceptibility to group A Steptococci is also controlled by a
single host genetic locus [122]. In contrast, a study by Yadav and colleagues [121] and
the present study revealed that susceptibility to the bacterial pathogens Yersina pestis and
Bp, respectively, involve multiple host loci. In fact, the only clear similarity between
these two studies was that two of the weaker QTLs involved in susceptibility to Yersinia
overlap with the QTL on chromosome 5 that was identified in the current studies on Bp.
These similarities could be coincidental, but they could also indicate some strong
similarities in the interactions of hosts with these two highly virulent intracellular
bacterial pathogens.

63

FUTURE STUDIES
Chromosomes 5 and 7 Are Co-Dependent
Whole genome linkage analysis of our survival phenotype revealed two
significant QTLs on chromosomes 5 and 7. The significant/suggestive regions of these
two chromosomes have roughly the same pattern of inheritance of B6 and D2 haplotypes
from the 32-BXD strain cohort used in the initial analysis. In other words, our significant
and suggestive intervals on chromosomes 5 and 7 are effectively one region of the
genome from a statistical point of view. GN incorporates a feature called composite
interval mapping, which can detect secondary QTLs and decipher if two loci are codependent or independent. Composite interval mapping revealed that these two loci are
co-dependent based on the loss of both QTLs when we controlled for loci within or near
the significant/suggestive QTL intervals for chromosomes 5 and 7.
While previous studies were completed using randomly selected BXD strains, to
resolve the co-dependency between chromosomes 5 and 7, we have begun adding
specifically selected strains to the previous analysis. These specifically selected strains
were chosen based on the results of a haplotype analysis that was completed using GN.
The haplotype analysis identified BXD genotypes (that were not used in the preliminary
studies) that have differing haplotypes (either B6 or D2) on chromosomes 5 and 7 in our
regions of interest. Same as previous studies, disease-state phenotypes (survival, time-todeath and weight loss) were measured using the selected BXD strains. Recently, we have
added three new BXD strains (BXD -44, -79, -100) to this analysis and interval mapping
revealed a highly significant QTL on chromosome 5 (Figure 6-2). The QTL peak on
chromosome 7 from our initial analysis was a presumed artifact attributable to the similar
pattern of inheritance in the initial BXD cohort and addition of these strains with
differing haplotypes, significantly decreased the QTL on chromosome 7. We will
continue to add specifically selected BXD strains to this study to increase the precision of
QTL analysis and significantly reduce the number of candidate genes.
The Additive Allele Effect for Survival QTL Analysis
Future studies will focus on an interesting phenomenon observed during our
survival QTL analysis involving the additive allele effect. The additive allele effect is an
estimate of the change in the average phenotype that would be produced by substituting a
D2 or B6 single allele, thereby increasing trait values [205, 206]. When observing a QTL
map generated by GN, the thin red and green lines indicate that B6 or D2 alleles increase
trait values, respectively, and the additive values are located on the far right of the QTL
map [205]. QTL maps of our survival phenotype display a thin green line, which is
indicative of a D2 allele increasing the survival trait in the suggestive/significant QTL
interval on chromosomes 5; but this observation does not conform to what we observe for
survival at the parental level. Based on our QTL maps, B6 should be a highly sensitive
strain and D2 should be a highly resistant strain. We postulate that something dramatic
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Figure 6-2. Refined QTL analysis with addition of three new BXD genotypes:
Genome-wide linkage analysis of survival following pneumonic challenge with
Burkholderia pseudomallei.
A cohort of male mice, which included 35 BXD strains, was infected intranasally with
50-100 CFU of Burkholderia pseudomallei. Infected mice were monitored for survival
for up to 11 days post-infection and those that survived infection were given a value of
“1” while those that succumbed to infection received a value of “0”. Panel A: Log-Rank
plot showing the mean± SEM of the survival value for each strain. Panels B and C:
Standard and weighted interval mapping, respectively, was performed using the in silico
resources within GeneNetwork.org to identify genetic loci that correlated with survival.
The blue line indicates LRS scores across the entire genome. Thin red and green lines
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases
for each chromosome, and the y-axis represents the LRS score. Thick red and grey
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive
threshold (p<0.63), respectively.
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has happened in this region of the genome in one of the parent strains that has caused a
reverse in the polarity. However, it is unlikely that both strains were subject to a serious
mutation that would cause this type of reverse in polarity. Undeniably, this phenomenon
raises the following question: In the last 20 years, has there been a serious mutation in D2
that has made it more sensitive to Bp or has there been a mutation in B6 that has made it
highly resistant to Bp? A haplotype analysis revealed that mice with a B allele within our
QTL intervals on chromosome 5 succumb to Bp infection, while mice with a D allele
display an increased survival phenotype to the infection.
One way to begin dissecting this interesting observation is to perform Bp survival
studies with C57BL/6NJ (B6NJ) mice. Using B6NJ mice will allow us to test the idea
that there has been a novel or spontaneous mutation in the B6 strain that has permitted
them to survive Bp infections. In 1951, The Jackson Laboratory sent B6 mice (at F32
generation) to the National Institutes of Health, where they were maintained and bred
independently for decades [207]. B6NJ is now considered a subline of C57BL/6. As such,
if a recent mutation is the cause of the increased survivability in the B6 mice, then the
B6NJ strains would be devoid of this mutation and exhibit a decreased survival
phenotype. Conversely, this same study could be carried out with D2 mice using DBA/1J
(D1). D2 and D1 differ at a large number of loci (including the MHC H2 haplotype).
CONCLUSIONS
The mapping of host resistance and susceptibility loci in the BXD RI population
uncovered several QTLs and potential candidate genes that may be critical for host
defense during melioidosis. The data presented in this dissertation provides an intriguing
glimpse into the genetic basis of the differential susceptibility to a Bp infection. Our data
indicate that genetic regulation of survival, time-to-death and weight loss during a Bp
infection is a complex phenomenon, whereby many genes exert their effects on these
traits. Weight loss QTLs displayed a time-dependent profile indicating host loci within
these QTLs may be important for the host response in a transient and dynamic fashion.
Furthermore, linkage analysis of survival (and time-to-death) generated two significant
QTLs, but we were able to narrow down these QTL regions to chromosome 5 only using
specifically selected BXD strains. We examined these QTL regions and identified several
possible candidate genes that may be important for host response to Bp infections. These
studies will lay the groundwork in increasing our understanding of the interactions
between Bp and its genetically diverse hosts.
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APPENDIX.
Table A-1.

SUPPLEMENTARY FIGURES AND TABLES

BXD strain group sizes from day 1 through day 4.

Day #1

Day #2

Day #3

Day #4

Mouse
Strain
C57BL/6J

n=# of
mice
n=23

Mouse
Strain
C57BL/6J

n=# of
mice
n=23

Mouse
Strain
C57BL/6J

n=# of
mice
n=23

Mouse
Strain
C57BL/6J

n=# of
mice
n=23

DBA

n=23

DBA

n=23

*DBA

n=22

*DBA

n=3

BXD 27

n=1

BXD 27

n=1

BXD 27

n=1

BXD 27

n=1

BXD 22

n=3

BXD 22

n=3

BXD 22

n=3

BXD 22

n=3

BXD 90

n=6

BXD 90

n=6

BXD 90

n=6

BXD 90

n=6

BXD 55

n=11

BXD 55

n=11

BXD 55

n=11

BXD 55

n=11

BXD 49

n=8

BXD 49

n=8

BXD 49

n=8

BXD 49

n=8

BXD 81

n=8

BXD 81

n=8

BXD 81

n=8

*BXD 81

n=4

BXD 73

n=10

BXD 73

n=10

BXD 73

n=10

*BXD 73

n=6

BXD 87

n=8

BXD 87

n=8

BXD 87

n=8

BXD 87

n=8

BXD 95

n=2

BXD 95

n=2

BXD 95

n=2

BXD 95

n=2

BXD 103

n=12

BXD 103

n=12

*BXD 103

n=11

*BXD 103

n=10

BXD 9

n=6

BXD 9

n=6

*BXD 9

n=5

*BXD 9

n=3

BXD 45

n=3

BXD 45

n=3

BXD 45

n=3

BXD 45

n=3

BXD 75

n=6

BXD 75

n=6

BXD 75

n=6

BXD 75

n=6

BXD 50

n=5

BXD 50

n=5

BXD 50

n=5

BXD 50

n=5

BXD 63

n=4

BXD 63

n=4

BXD 63

n=4

*BXD 63

n=1

BXD 101

n=1

BXD 101

n=1

BXD 101

n=1

BXD 101

n=1

BXD 65

n=1

BXD 65

n=1

BXD 65

n=1

BXD 65

n=1

BXD 96

n=12

BXD 96

n=12

BXD 96

n=12

*BXD 96

n=9

BXD 74

n=8

BXD 74

n=8

BXD 74

n=8

BXD 74

n=8

BXD 80

n=4

BXD 80

n=4

BXD 80

n=4

BXD 80

n=4

BXD 67

n=8

BXD 67

n=8

BXD 67

n=8

*BXD 67

n=5

BXD 64

n=19

BXD 64

n=19

BXD 64

n=19

*BXD 64

n=14

BXD 86

n=10

BXD 86

n=10

BXD 86

n=10

*BXD 86

n=2

BXD 13

n=4

BXD 13

n=4

BXD 13

n=4

*BXD 13

n=1

BXD 12

n=4

BXD 12

n=4

BXD 12

n=4

BXD 12

n=4

BXD 43

n=11

BXD 43

n=11

BXD 43

n=11

*BXD 43

n=8

BXD 1

n=2

BXD 1

n=2

BXD 1

n=2

*BXD 1

n=1

BXD 62

n=16

BXD 62

n=16

BXD 62

n=16

*BXD 62

n=12

BXD 69

n=5

BXD 69

n=5

BXD 69

n=5

*BXD 69

n=4

84

Table A-1.

(Continued).

Day #1

Day #2

Day #3

Day #4

Mouse
Strain
BXD 66

n=# of
mice
n=4

Mouse
Strain
BXD 66

n=# of
mice
n=4

Mouse
Strain
BXD 66

n=# of
mice
n=4

Mouse
Strain
BXD 66

n=# of
mice
n=4

BXD 68

n=4

BXD 68

n=4

BXD 68

n=4

*BXD 68

n=1

BXD 38

n=1

BXD 38

n=1

BXD 38

n=1

BXD 38

n=1

Red asterisk (*) indicates that at least one mouse from that genotype succumbed to
infection.
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Figure A-1. Genome-wide linkage analysis for percentage weight loss on days 5-11
post-Bp infection.
Genome-wide interval maps of percentage weight loss of all BXD genotypes and parental
strains at each time point are shown as indicated. Days 5, 8 and 9 show a significant QTL
on chromosome 12 while days 6, 7, 10, 11 show a suggestive QTL on chromosome 12.
The blue line indicates LRS scores across the entire genome. Thin red and green lines
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases
for each chromosome, and the y-axis represents the LRS score. Thick red and grey
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive
threshold (p<0.63), respectively.
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Table A-2. Pathway analysis (Gene Ontology (GO) Description) using genes whose
expression is significantly upregulated in resistant BXD mice (BXD50 and BXD70).
GO-Description

Count

%

P-Value

Benjamini

immune response

56

14.1

3.60E-28

5.80E-25

defense response

32

8.1

5.50E-10

2.90E-07

response to wounding

21

5.3

1.20E-05

2.10E-03

response to organic substance

19

4.8

8.50E-03

3.10E-01

regulation of cell proliferation

19

4.8

1.50E-02

4.30E-01

regulation of apoptosis

18

4.5

3.70E-02

6.00E-01

regulation of programmed cell death

18

4.5

4.10E-02

6.20E-01

regulation of cell death

18

4.5

4.30E-02

6.20E-01

inflammatory response

16

4

2.90E-05

4.60E-03

response to virus

15

3.8

1.50E-10

1.20E-07

antigen processing and presentation

14

3.5

9.90E-09

4.00E-06

positive regulation of immune
system process
behavior

14

3.5

1.70E-04

1.60E-02

14

3.5

4.80E-02

6.40E-01

innate immune response

12

3

6.20E-06

1.40E-03

positive regulation of immune
response
positive regulation of response to
stimulus
positive regulation of apoptosis

11

2.8

2.80E-04

2.30E-02

11

2.8

3.10E-03

1.60E-01

11

2.8

2.10E-02

5.00E-01

positive regulation of programmed
cell death
positive regulation of cell death

11

2.8

2.20E-02

5.10E-01

11

2.8

2.30E-02

5.10E-01

regulation of lymphocyte mediated
immunity
regulation of leukocyte mediated
immunity
regulation of immune effector
process
positive regulation of multicellular
organismal process

10

2.5

3.80E-06

1.00E-03

10

2.5

7.00E-06

1.40E-03

10

2.5

4.60E-05

6.10E-03

10

2.5

4.20E-03

1.90E-01

lymphocyte activation

10

2.5

1.10E-02

3.70E-01

leukocyte activation

10

2.5

2.50E-02

5.20E-01

locomotory behavior

10

2.5

4.10E-02

6.20E-01

cell activation

10

2.5

4.70E-02

6.40E-01

regulation of cytokine production

9

2.3

5.30E-03

2.30E-01
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Table A-2. (Continued).
GO-Description

Count

%

P-Value

Benjamini

induction of programmed cell death

9

2.3

1.50E-02

4.30E-01

induction of apoptosis

9

2.3

1.50E-02

4.30E-01

positive regulation of signal
transduction
response to endogenous stimulus

9

2.3

1.80E-02

4.60E-01

9

2.3

2.50E-02

5.20E-01

positive regulation of cell
communication
regulation of cell killing

9

2.3

2.90E-02

5.40E-01

8

2

1.20E-06

3.90E-04

regulation of leukocyte mediated
cytotoxicity
regulation of adaptive immune
response based on somatic
recombination of immune receptors
built from immunoglobulin
superfamily domains
regulation of adaptive immune
response
T cell activation

8

2

1.20E-06

3.90E-04

8

2

9.00E-05

9.70E-03

8

2

9.00E-05

9.70E-03

8

2

6.90E-03

2.70E-01

immune effector process

8

2

1.10E-02

3.60E-01

positive regulation of transport

8

2

1.30E-02

4.10E-01

regulation of lymphocyte activation

8

2

2.10E-02

5.00E-01

regulation of leukocyte activation

8

2

2.90E-02

5.50E-01

regulation of cell activation

8

2

3.00E-02

5.50E-01

regulation of protein modification
process
response to hormone stimulus

8

2

3.90E-02

6.20E-01

8

2

3.90E-02

6.20E-01

antigen processing and presentation
of peptide antigen

7

1.8

4.70E-05

5.80E-03

positive regulation of leukocyte
mediated immunity
positive regulation of lymphocyte
mediated immunity

7

1.8

1.00E-04

1.00E-02

7

1.8

1.00E-04

1.00E-02

positive regulation of immune
effector process
lipoprotein metabolic process

7

1.8

2.30E-04

2.00E-02

7

1.8

3.30E-03

1.70E-01

regulation of T cell activation

7

1.8

1.80E-02

4.60E-01

regulation of protein amino acid
phosphorylation
positive regulation of cell killing

7

1.8

2.90E-02

5.40E-01

6

1.5

6.30E-05

7.20E-03

6

1.5

4.40E-04

3.20E-02

positive regulation of adaptive immune
response based on somatic recombination
of immune receptors built from
immunoglobulin superfamily domains
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Table A-2. (Continued).
GO-Description

Count

%

P-Value

Benjamini

positive regulation of adaptive
immune response
positive regulation of cytokine
production
negative regulation of immune
system process
adaptive immune response

6

1.5

4.40E-04

3.20E-02

6

1.5

6.60E-03

2.70E-01

6

1.5

1.50E-02

4.30E-01

6

1.5

2.20E-02

5.10E-01

adaptive immune response based on
somatic recombination of immune
receptors built from
immunoglobulin superfamily
domains
negative regulation of multicellular
organismal process

6

1.5

2.20E-02

5.10E-01

6

1.5

4.30E-02

6.30E-01

regulation of T cell mediated
cytotoxicity
regulation of T cell mediated
immunity
antigen processing and presentation
of exogenous antigen

5

1.3

3.90E-05

5.70E-03

5

1.3

3.20E-04

2.50E-02

5

1.3

1.90E-03

1.10E-01

positive regulation of defense
response
antigen processing and presentation
via MHC class Ib

5

1.3

2.30E-02

5.00E-01

4

1

2.30E-04

1.90E-02

positive regulation of T cell
mediated cytotoxicity
positive regulation of T cell
mediated immunity
regulation of interleukin-12
production

4

1

5.30E-04

3.70E-02

4

1

1.70E-03

1.10E-01

4

1

2.70E-03

1.50E-01

antigen processing and presentation
of peptide antigen via MHC class I

4

1

3.90E-03

1.90E-01

regulation of natural killer cell
mediated cytotoxicity
regulation of natural killer cell
mediated immunity
antigen processing and presentation
of exogenous peptide antigen

4

1

6.20E-03

2.60E-01

4

1

6.20E-03

2.60E-01

4

1

9.20E-03

3.30E-01

regulation of interferon-gamma
production
response to cytokine stimulus

4

1

2.30E-02

5.10E-01

4

1

2.30E-02

5.10E-01

negative regulation of mononuclear
cell proliferation
negative regulation of leukocyte
proliferation
negative regulation of lymphocyte
proliferation

4

1

2.90E-02

5.40E-01

4

1

2.90E-02

5.40E-01

4

1

2.90E-02

5.40E-01
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Table A-2. (Continued).
GO-Description

Count

%

P-Value

Benjamini

cell growth

4

1

3.30E-02

5.70E-01

positive regulation of cytokine
biosynthetic process
antigen processing and presentation
of endogenous peptide antigen
positive regulation of glucose
transport
positive regulation of glucose
import
positive regulation of interleukin-12
biosynthetic process

4

1

4.60E-02

6.40E-01

3

0.8

2.10E-03

1.20E-01

3

0.8

7.20E-03

2.80E-01

3

0.8

7.20E-03

2.80E-01

3

0.8

7.20E-03

2.80E-01

regulation of interleukin-12
biosynthetic process
regulation of fibroblast growth
factor receptor signaling pathway

3

0.8

1.20E-02

3.80E-01

3

0.8

1.80E-02

4.60E-01

regulation of peptidyl-serine
phosphorylation
cytokine metabolic process

3

0.8

1.80E-02

4.60E-01

3

0.8

2.90E-02

5.50E-01

defense response to virus

3

0.8

3.30E-02

5.70E-01

cell structure disassembly during
apoptosis
positive regulation of natural killer
cell mediated immunity

3

0.8

3.30E-02

5.70E-01

3

0.8

3.30E-02

5.70E-01

positive regulation of natural killer
cell mediated cytotoxicity

3

0.8

3.30E-02

5.70E-01

positive regulation of interferongamma production
negative regulation of neurological
system process
antigen processing and presentation
of endogenous peptide antigen via
MHC class Ib

3

0.8

4.10E-02

6.10E-01

3

0.8

4.60E-02

6.40E-01

2

0.5

3.80E-02

6.10E-01

Count - number of genes from list involved in GO Description; % - percentage of all
genes in list; P-value - modified Fisher Exact p-value for enrichment; Benjamini - false
discovery rate corrected P-values.
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Table A-3. Pathway analysis (Gene Ontology (GO) Description) using genes whose
expression is significantly upregulated in susceptible BXD mice (BXD9, BXD63 and
BXD27).
GO-Description

Count

%

P-Value

Benjamini

vesicle-mediated transport

16

6.2

1.80E-04

6.80E-02

membrane organization

14

5.4

9.20E-06

5.20E-03

defense response

13

5

3.80E-03

5.80E-01

endocytosis

12

4.7

7.00E-06

7.90E-03

membrane invagination

12

4.7

7.00E-06

7.90E-03

response to wounding

10

3.9

1.40E-02

8.40E-01

intracellular transport

10

3.9

4.80E-02

9.00E-01

ion homeostasis

9

3.5

1.50E-02

8.30E-01

translation

9

3.5

2.40E-02

9.00E-01

chemical homeostasis

9

3.5

4.80E-02

8.90E-01

cellular ion homeostasis

8

3.1

2.50E-02

8.90E-01

cellular chemical
homeostasis
positive regulation of
multicellular organismal
process
inflammatory response

8

3.1

2.80E-02

8.90E-01

7

2.7

9.10E-03

7.80E-01

7

2.7

3.80E-02

8.80E-01

defense response to
bacterium
response to bacterium

6

2.3

6.70E-03

7.20E-01

6

2.3

2.90E-02

8.80E-01

phagocytosis

4

1.6

1.60E-02

8.20E-01

response to hypoxia

4

1.6

3.30E-02

8.80E-01

response to oxygen levels

4

1.6

3.40E-02

8.80E-01

regulation of cAMP
metabolic process
regulation of cyclic
nucleotide metabolic
process
regulation of nucleotide
metabolic process

4

1.6

3.70E-02

8.80E-01

4

1.6

4.60E-02

9.00E-01

4

1.6

4.90E-02

8.90E-01

inflammatory response to
antigenic stimulus

3

1.2

2.40E-03

5.00E-01

cell killing

3

1.2

1.30E-02

8.40E-01

positive regulation of
phagocytosis
regulation of phagocytosis

3

1.2

2.60E-02

8.80E-01

3

1.2

3.00E-02

8.70E-01

antibody-dependent cellular
cytotoxicity

2

0.8

4.30E-02

9.00E-01

type IIa hypersensitivity

2

0.8

4.30E-02

9.00E-01

type II hypersensitivity

2

0.8

4.30E-02

9.00E-01
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Table A-3.

(Continued).

Count - number of genes from list involved in GO Description; % - percentage of all
genes in list; P-value - modified Fisher Exact p-value for enrichment; Benjamini - false
discovery rate corrected P-values.
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